

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/10414 A2

(51) International Patent Classification⁷: **C12N 15/82**,
15/67, 15/62, C07K 14/56

(21) International Application Number: PCT/US01/23400

(22) International Filing Date: 26 July 2001 (26.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/221,705 31 July 2000 (31.07.2000) US
60/293,330 23 May 2001 (23.05.2001) US

(71) Applicant (for all designated States except US): **BIOLEX, INC.** [US/US]; 158 Credle Street, Pittsboro, NC 27312 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STOMP**, Anne-Marie [US/US]; 565 East River Road, Moncure, NC 27559 (US). **DICKEY, Lynn** [US/US]; 111 Buckden Place, Cary, NC 27511 (US). **GASDASKA, John** [US/US]; 102 Lisa Drive, Carrboro, NC 27510 (US).

(74) Agents: **COULTER, Kathryn, L.** et al.; Alston & Bird LLP, Bank of America Plaza, Suite 4000, 101 South Tryon Street, Charlotte, NC 28280-4000 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES IN DUCKWEED

Example 1: Relative IFN Levels in Tissue and Media



(57) Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.

WO 02/10414 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES IN DUCKWEED

FIELD OF THE INVENTION

The present invention relates to methods and compositions for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed.

5 BACKGROUND OF THE INVENTION

The duckweeds are the sole members of the monocotyledonous family Lemnaceae. The four genera and 34 species are all small, free-floating, fresh-water plants whose geographical range spans the entire globe (Landolt (1986)
10 *Biosystematic Investigation on the Family of Duckweeds: The Family of Lemnaceae—A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich). Although the most morphologically reduced plants known, most duckweed species have all the tissues and organs of much larger plants, including roots, stems, flowers, seeds and fronds. Duckweed species have been studied extensively and a substantial literature
15 exists detailing their ecology, systematics, life-cycle, metabolism, disease and pest susceptibility, their reproductive biology, genetic structure, and cell biology. (Hillman (1961) *Bot. Review* 27: 221; Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The Family of Lemnaceae—A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich).

20 The growth habit of the duckweeds is ideal for microbial culturing methods. The plant rapidly proliferates through vegetative budding of new fronds, in a macroscopic manner analogous to asexual propagation in yeast. This proliferation occurs by vegetative budding from meristematic cells. The meristematic region is small and is found on the ventral surface of the frond. Meristematic cells lie in two
25 pockets, one on each side of the frond midvein. The small midvein region is also the site from which the root originates and the stem arises that connects each frond to its mother frond. The meristematic pocket is protected by a tissue flap. Fronds bud

alternately from these pockets. Doubling times vary by species and are as short as 20-24 hours (Landolt (1957) *Ber. Schweiz. Bot. Ges.* 67: 271; Chang *et al.* (1977) *Bull. Inst. Chem. Acad. Sin.* 24:19; Datko and Mudd (1970) *Plant Physiol.* 65:16; Venkataraman *et al.* (1970) *Z. Pflanzenphysiol.* 62: 316).

- 5 Intensive culture of duckweed results in the highest rates of biomass accumulation per unit time (Landolt and Kandeler (1987) *The Family of Lemnaceae—A Monographic Study Vol. 2: Phytochemistry, Physiology, Application, Bibliography*, Veroffentlichungen des Geobotanischen Institutes ETH, Stiftung Rubel, Zurich), with dry weight accumulation ranging from 6-15% of fresh weight (Tillberg *et al.* (1979) *Physiol. Plant.* 46:5; Landolt (1957) *Ber. Schweiz. Bot. Ges.* 67:271; Stomp, unpublished data). Protein content of a number of duckweed species grown under varying conditions has been reported to range from 15-45% dry weight (Chang *et al.* (1977) *Bull. Inst. Chem. Acad. Sin.* 24:19; Chang and Chui (1978) *Z. Pflanzenphysiol.* 89:91; Porath *et al.* (1979) *Aquatic Botany* 7:272; Appenroth *et al.* (1982) *Biochem. Physiol. Pflanz.* 177:251). Using these values, the level of protein production per liter of medium in duckweed is on the same order of magnitude as yeast gene expression systems.

- Sexual reproduction in duckweed is controlled by medium components and culturing conditions, including photoperiod and culture density. Flower induction is a routine laboratory procedure with some species. Plants normally self-pollinate, and selfing can be accomplished in the laboratory by gently shaking cultures. By this method, inbred lines of *Lemna gibba* have been developed. Spontaneous mutations have been identified (Slovin and Cohen (1988) *Plant Physiol.* 86, 522), and chemical and gamma ray mutagenesis (using EMS or NMU) have been used to produce mutants with defined characteristics. Outcrossing of *L. gibba* is tedious but can be done by controlled, hand pollination. The genome size of the duckweeds varies from 0.25-1.63 pg DNA/2C with chromosome counts ranging from 20 to 80 and averaging about 40 across the Lemnaceae (Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The family of Lemnaceae—A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich). Ploidy levels are estimated to range from 2-12 C. Id. Genetic diversity within the Lemnaceae has been investigated using secondary products, isozymes, and DNA sequences (McClure and Alston

(1966) *Nature* 4916:311; McClure and Alston (1966) *Amer. J. Bot.* 53:849; Vasseur *et al.* (1991) *Pl. Syst. Evol.* 177:139 (1991); Crawford and Landolt (1993) *Syst. Bot.* 10:389).

Duckweed plant or duckweed nodule cultures can be efficiently transformed
5 with an expression cassette containing a nucleotide sequence of interest by any one of
a number of methods including *Agrobacterium*-mediated gene transfer, ballistic
bombardment, or electroporation. Stable duckweed transformants can be isolated by
transforming the duckweed cells with both the nucleotide sequence of interest and a
gene which confers resistance to a selection agent, followed by culturing the
10 transformed cells in a medium containing the selection agent. See U.S. Patent No.
6,040,498 to Stomp *et al.*

A duckweed gene expression system provides the pivotal technology that
would be useful for a number of research and commercial applications. For plant
molecular biology research as a whole, a differentiated plant system that can be
15 manipulated with the laboratory convenience of yeast provides a very fast system in
which to analyze the developmental and physiological roles of isolated genes. For
commercial production of valuable polypeptides, a duckweed-based system has a
number of advantages over existing microbial or cell culture systems. Plants
demonstrate post-translational processing that is similar to mammalian cells,
20 overcoming one major problem associated with the microbial cell production of
biologically active mammalian polypeptides, and it has been shown by others (Hiatt
(1990) *Nature* 334:469) that plant systems have the ability to assemble multi-subunit
proteins, an ability often lacking in microbial systems. Scale-up of duckweed biomass
to levels necessary for commercial production of recombinant proteins is faster and
25 more cost efficient than similar scale-up of mammalian cells, and unlike other
suggested plant production systems, e.g., soybeans and tobacco, duckweed can be
grown in fully contained and controlled biomass production vessels, making the
system's integration into existing protein production industrial infrastructure far
easier.

30 These characteristics make duckweed an ideal choice to develop as an
efficient, plant-based system for the production of recombinant proteins.
Accordingly, the present invention provides methods and compositions that increase

the efficiency of the duckweed gene expression system as a tool for producing biologically active polypeptides.

SUMMARY OF THE INVENTION

5

The present invention is drawn to methods and compositions for the expression and recovery of biologically active recombinant polypeptides, using duckweed as the expression system. One aspect of the present invention provides a method for enhanced expression levels of biologically active polypeptides in
10 duckweed, resulting in an increased polypeptide yield and enabling the production of useful quantities of valuable biologically active polypeptides in this system. Another aspect of the invention discloses methods for the directed secretion of biologically active polypeptides from genetically engineered duckweed plant or duckweed nodule cultures. Secretion of the expressed polypeptide facilitates its recovery and prevents
15 the loss of activity that might result from the mechanical grinding or enzymatic lysing of the duckweed tissue.

In one embodiment, the invention encompasses a method of producing a biologically active recombinant polypeptide in a duckweed plant culture or a duckweed nodule culture, comprising the steps of: (a) culturing within a duckweed
20 culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the polypeptide and an operably linked coding
25 sequence for a signal peptide that directs secretion of the polypeptide into the culture medium; and (b) collecting said biologically active polypeptide from the duckweed culture medium. In some embodiments of this method, the nucleotide sequence has at least one attribute selected from the group consisting of: (a) duckweed-preferred codons in the coding sequence for said polypeptide; (b) duckweed-preferred codons
30 in the coding sequence for said signal peptide; (c) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and (d) an operably linked nucleotide sequence comprising a plant intron that is inserted

upstream of the coding sequence. In some embodiments of this method, the biologically active recombinant polypeptide is secreted into the duckweed culture medium.

In another embodiment, the invention encompasses a method of secreting a biologically active recombinant polypeptide in a duckweed plant culture or a duckweed nodule culture, comprising the steps of: (a) culturing within a duckweed culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the polypeptide into the culture medium; and (b) collecting said biologically active polypeptide from the duckweed culture medium. In some embodiments of this method, the nucleotide sequence has at least one attribute selected from the group consisting of: (a) duckweed-preferred codons in the coding sequence for said polypeptide; (b) duckweed-preferred codons in the coding sequence for said signal peptide; (c) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and (d) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence. In some embodiments of this method, the biologically active recombinant polypeptide is secreted into the duckweed culture medium.

In some embodiments of the above methods, the signal peptide is selected from the group consisting of: (a) the human α -2b-interferon signal sequence; (b) the *Arabidopsis thaliana* chitinase signal sequence; (c) the rice α -amylase signal sequence; (d) the modified rice α -amylase sequence; (e) a duckweed signal sequence; and (f) a signal sequence native to the biologically active recombinant polypeptide. In one embodiment of the method, the signal peptide is the rice α -amylase signal peptide whose sequence is set forth in SEQ ID NO:3.

In some embodiments of the above methods, the duckweed-preferred codons are *Lemna*-preferred codons. In further embodiments, the duckweed-preferred codons

are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons. In further embodiments, at least one coding sequence selected from the coding sequence for the biologically active recombinant polypeptide and the coding sequence for the signal peptide comprises between 70-100 % *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons..

In other embodiments, the invention encompasses a method of producing a biologically active recombinant polypeptide, comprising the steps of: (a) culturing a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is encoded by a nucleotide sequence that has been modified for enhanced expression in duckweed, and (b) collecting said biologically active polypeptide from said duckweed plant culture or said duckweed nodule culture. In some embodiments of this method, the nucleotide sequence that has been modified for enhanced expression in duckweed has at least one attribute selected from the group consisting of: (a) duckweed-preferred codons in the coding sequence for said biologically active recombinant polypeptide; (b) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and (c) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence.

In some embodiments of this method, the duckweed-preferred codons are *Lemna*-preferred codons. In further embodiments, the duckweed-preferred codons are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons. In further embodiments, the coding sequence comprises between 70-100 % *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons.

In some embodiments of the above methods, the plant-preferred translation initiation context nucleotide sequence consists of the nucleotide sequence "ACC" or "ACA", wherein said context is positioned immediately adjacent to the 5' end of the translation initiation codon.

In some embodiments of the above methods, the operably linked nucleotide sequence comprising said plant intron is the sequence set forth in SEQ ID NO:1.

In some embodiments of any of the above methods, the duckweed frond culture or duckweed nodule culture expresses and assembles all of the subunits of a biologically active multimeric protein. In further embodiments, the multimeric protein is selected from the group consisting of collagen, hemoglobin, P450 oxidase, and a monoclonal antibody.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is a mammalian polypeptide. In further embodiments, the mammalian polypeptide is a therapeutic polypeptide. In some embodiments, the mammalian polypeptide is selected from the group consisting of: insulin, growth hormone, α -interferon, β -interferon, β -glucocerebrosidase, β -glucuronidase, retinoblastoma protein, p53 protein, angiostatin, leptin, monoclonal antibodies, cytokines, receptors, human vaccines, animal vaccines, plant polypeptides, and serum albumin.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is α -2b-interferon. In further embodiments, the α -2b-interferon is human α -2b-interferon. In further embodiments, the human α -2b-interferon has the amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:5.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is a biologically active variant of α -2b-interferon, wherein said biologically active variant has at least 80% sequence identity with SEQ ID NO:4 or SEQ ID NO:5.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is an enzyme.

In other embodiments, the invention encompasses the stably transformed duckweed plant culture or duckweed nodule culture of any of the above methods. In further embodiments, the stably transformed duckweed plant culture or duckweed nodule culture is selected from the group consisting of the genus *Spirodela*, genus *Wolffia*, genus *Wolffiella*, and genus *Lemna*. In further embodiments, the stably transformed duckweed plant culture or duckweed nodule culture is selected from the group consisting of *Lemna minor*, *Lemna miniscula*, *Lemna aequinoctialis*, and *Lemna gibba*.

In other embodiments, the invention encompasses a nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) the amino acid sequence set forth in SEQ ID NO:4; (b) the amino acid sequence set forth in SEQ ID NO:5; (c) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:4, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:4; and (d) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:5, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:5; wherein the nucleotide sequence comprises duckweed-preferred codons. In further embodiments, the nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO:2.

In other embodiments, the invention encompasses a nucleic acid molecule comprising a nucleotide sequence encoding a signal peptide selected from the group consisting of: (a) the rice α -amylase signal peptide amino acid sequence set forth in SEQ ID NO:6; and (b) the modified rice-amylase signal peptide amino acid sequence set forth in SEQ ID NO:7; wherein the nucleotide sequence comprises duckweed-preferred codons. In further embodiments, the nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO: 3.

In other embodiments, the invention encompasses a nucleic acid molecule for the expression and secretion of human α -2b-interferon in duckweed comprising the signal peptide-encoding nucleotide sequence given in SEQ ID NO:3, and the mature human α -2b-interferon-encoding nucleotide sequence given in SEQ ID NO:5, wherein the signal peptide-encoding nucleotide sequence and said mature human α -2b-interferon-encoding nucleotide sequence are operably linked. In further embodiments, the nucleic acid molecule additionally comprises the intron-comprising nucleotide sequence given in SEQ ID NO:1, wherein said intron-comprising nucleotide sequence is operably linked to said signal peptide-encoding nucleotide sequence and said mature human α -2b-interferon-encoding nucleotide sequence.

These and other aspects of the present invention are disclosed in more detail in the description of the invention given below.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1

5 Figure 1 show the interferon levels (as determined by a solid phase sandwich immunoassay) in the media and tissue of a transformed duckweed culture, as described Example 1.

Figure 2

10 Figure 2 show the interferon levels (as determined by a solid phase sandwich immunoassay) in the media and tissue of a transformed duckweed cultures, as described in Example 2.

DETAILED DESCRIPTION OF THE INVENTION

15

In the present invention, methods are disclosed for improving the expression and the recovery of biologically active polypeptides from genetically engineered duckweed plants and duckweed nodule cultures. These methods comprise the steps of

(1) culturing a stably transformed duckweed plant or a duckweed nodule
20 culture that expresses at least one biologically active polypeptide, wherein the polypeptide is encoded by a nucleotide sequence that has been modified for enhanced expression in duckweed, and recovering the biologically active polypeptide from the duckweed culture. Modifications to the nucleotide sequence that are encompassed by this invention include, but are not limited to, the use of duckweed-preferred codons
25 for the coding sequence, the use of a plant-preferred translation initiation context nucleotide sequence for the translation initiation codon, and the insertion of a nucleotide sequence comprising a plant intron sequence upstream of the sequence encoding the polypeptide.

30 (2) Culturing a stably transformed duckweed plant or duckweed nodule culture that expresses at least one biologically active polypeptide comprising a signal sequence that directs secretion of the polypeptide into the culture medium, followed

by recovering the biologically active polypeptide from the culture medium. In one embodiment of this method, the nucleotide sequence encoding the biologically active polypeptide is modified for enhanced expression in duckweed. Alternatively, in another embodiment the nucleotide sequence encoding the signal peptide is modified for enhanced expression in duckweed. In one embodiment, the nucleotide sequence encoding both the biologically active polypeptide and the signal peptide are modified for enhanced expression in duckweed.

As another aspect, the present invention encompasses transformed duckweed plants or duckweed nodule cultures producing biologically active polypeptides according to the methods above.

As another aspect, the present invention discloses methods and nucleic acid sequences for producing biologically active human α -2b-interferon in duckweed.

Definitions:

"Polypeptide" refers to any monomeric or multimeric protein or peptide.

"Biologically active polypeptide" refers to a polypeptide that has the capability of performing one or more biological functions or a set of activities normally attributed to the polypeptide in a biological context. Those skilled in the art will appreciate that the term "biologically active" includes polypeptides in which the biological activity is altered as compared with the native protein (e.g., suppressed or enhanced), as long as the protein has sufficient activity to be of interest for use in industrial or chemical processes or as a therapeutic, vaccine, or diagnostics reagent. Biological activity can be determined by any method available in the art. For example, the biological activity of members of the interferon family of proteins can be determined by any of a number of methods including their interaction with interferon-specific antibodies, their ability to increase resistance to viral infection, or their ability to modulate the transcription of interferon-regulated gene targets.

"Nucleotide sequence of interest" as used herein refers to any nucleotide sequence encoding a polypeptide intended for expression in duckweed. For example, nucleotide sequences encoding therapeutic (e.g., for veterinary or medical uses) or immunogenic (e.g., for vaccination) polypeptides can be expressed using transformed duckweed according to the present invention.

The terms "expression" or "production" refer to the biosynthesis of a gene product, including the transcription, translation, and assembly of said gene product.

The term "duckweed" refers to members of the family Lemnaceae. This family currently is divided into four genera and 34 species of duckweed as follows:

5 genus *Lemna* (*L. aequinoctialis*, *L. disperma*, *L. ecuadoriensis*, *L. gibba*, *L. japonica*, *L. minor*, *L. miniscula*, *L. obscura*, *L. perpusilla*, *L. tenera*, *L. trisulca*, *L. turionifera*, *L. valdiviana*); genus *Spirodela* (*S. intermedia*, *S. polyrrhiza*, *S. punctata*); genus *Wolffia* (*Wa. angusta*, *Wa. arrhiza*, *Wa. australina*, *Wa. borealis*, *Wa. brasiliensis*, *Wa. columbiana*, *Wa. elongata*, *Wa. globosa*, *Wa. microscopica*, *Wa. neglecta*) and

10 genus *Wolffiella* (*Wl. caudata*, *Wl. denticulata*, *Wl. gladiata*, *Wl. hyalina*, *Wl. lingulata*, *Wl. repunda*, *Wl. rotunda*, and *Wl. neotropica*). Any other genera or species of Lemnaceae, if they exist, are also aspects of the present invention. *Lemna* species can be classified using the taxonomic scheme described by Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The family of Lemnaceae—*

15 *A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich.

The term "duckweed nodule culture" as used herein refers to a culture comprising duckweed cells wherein at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the cells are differentiated cells. A "differentiated cell," as used herein, is a cell with at least one phenotypic characteristic (e.g., a

20 distinctive cell morphology or the expression of a marker nucleic acid or protein) that distinguishes it from undifferentiated cells or from cells found in other tissue types. The differentiated cells of the duckweed nodule culture described herein form a tiled smooth surface of interconnected cells fused at their adjacent cell walls, with nodules that have begun to organize into frond primordium scattered throughout the tissue.

25 The surface of the tissue of the nodule culture has epidermal cells connect to each other via plasmadesmata.

"Duckweed-preferred codons" as used herein refers to codons that have a frequency of codon usage in duckweed of greater than 17%.

"*Lemna*-preferred codons" as used herein refers to codons that have a

30 frequency of codon usage in the genus *Lemna* of greater than 17%.

"*Lemna gibba*-preferred codons" as used herein refers to codons that have a frequency of codon usage in *Lemna gibba* of greater than 17% where the frequency of

codon usage in *Lemna gibba* was obtained from the Codon Usage Database (GenBank Release 113,0; at [http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+\[gbpln\]](http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+[gbpln])).

5 "Translation initiation codon" refers to the codon that initiates the translation of the mRNA transcribed from the nucleotide sequence of interest.

"Translation initiation context nucleotide sequence" as used herein refers to the identity of the three nucleotides directly 5' of the translation initiation codon.

"Secretion" as used herein refers to translocation of a polypeptide across both the plasma membrane and the cell wall of a host plant cell.

10 "Operably linked" as used herein in reference to nucleotide sequences refers to multiple nucleotide sequences that are placed in a functional relationship with each other. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in reading frame.

15 A. Expression Cassettes

According to the present invention, stably transformed duckweed is obtained by transformation with a nucleotide sequence of interest contained within an expression cassette. The expression cassette comprises a transcriptional initiation region linked to the nucleic acid or gene of interest. Such an expression cassette is
20 provided with a plurality of restriction sites for insertion of the gene or genes of interest (e.g., one gene of interest, two genes of interest, etc.) to be under the transcriptional regulation of the regulatory regions. The expression cassette may encode a single gene of interest. In particular embodiments of the invention, the nucleic acid to be transferred contains two or more expression cassettes, each of
25 which encodes at least one gene of interest.

The transcriptional initiation region, (e.g., a promoter) may be native or homologous or foreign or heterologous to the host, or could be the natural sequence or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation
30 region is introduced. As used herein a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

Any suitable promoter known in the art can be employed according to the present invention (including bacterial, yeast, fungal, insect, mammalian, and plant promoters). For example, plant promoters, including duckweed promoters, may be used. Exemplary promoters include, but are not limited to, the Cauliflower Mosaic Virus 35S promoter, the opine synthetase promoters (e.g., nos, mas, ocs, etc.), the ubiquitin promoter, the actin promoter, the ribulose biphosphate (RubP) carboxylase small subunit promoter, and the alcohol dehydrogenase promoter. The duckweed RubP carboxylase small subunit promoter is known in the art (Silverthorne *et al.* (1990) *Plant Mol. Biol.* 15:49). Other promoters from viruses that infect plants, preferably duckweed, are also suitable including, but not limited to, promoters isolated from Dasheen mosaic virus, Chlorella virus (e.g., the Chlorella virus adenine methyltransferase promoter; Mitra *et al.* (1994) *Plant Mol. Biol.* 26:85), tomato spotted wilt virus, tobacco rattle virus, tobacco necrosis virus, tobacco ring spot virus, tomato ring spot virus, cucumber mosaic virus, peanut stump virus, alfalfa mosaic virus, sugarcane bacilliform badnavirus and the like.

Finally, promoters can be chosen to give a desired level of regulation. For example, in some instances, it may be advantageous to use a promoter that confers constitutive expression (e.g., the mannopine synthase promoter from *Agrobacterium tumefaciens*). Alternatively, in other situations, it may be advantageous to use promoters that are activated in response to specific environmental stimuli (e.g., heat shock gene promoters, drought-inducible gene promoters, pathogen-inducible gene promoters, wound-inducible gene promoters, and light/dark-inducible gene promoters) or plant growth regulators (e.g., promoters from genes induced by abscissic acid, auxins, cytokinins, and gibberellic acid). As a further alternative, promoters can be chosen that give tissue-specific expression (e.g., root, leaf, and floral-specific promoters).

The overall strength of a given promoter can be influenced by the combination and spatial organization of cis-acting nucleotide sequences such as upstream activating sequences. For example, activating nucleotide sequences derived from the *Agrobacterium tumefaciens* octopine synthase gene can enhance transcription from the *Agrobacterium tumefaciens* mannopine synthase promoter (see U.S. Patent 5,955,646 to Gelvin *et al.*). In the present invention, the expression cassette can

contain activating nucleotide sequences inserted upstream of the promoter sequence to enhance the expression of the nucleotide sequence of interest. In one embodiment, the expression cassette includes three upstream activating sequences derived from the *Agrobacterium tumefaciens* octopine synthase gene operably linked to a promoter
5 derived from an *Agrobacterium tumefaciens* mannopine synthase gene (see U.S. Patent 5,955,646, herein incorporated by reference).

The transcriptional cassette includes in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a nucleotide sequence of interest, and a transcriptional and translational termination region functional in plants. Any
10 suitable termination sequence known in the art may be used in accordance with the present invention. The termination region may be native with the transcriptional initiation region, may be native with the nucleotide sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthetase and nopaline synthetase
15 termination regions. See also Guerineau *et al.* (1991) *Mol. Gen. Genet.* 262:141; Proudfoot (1991) *Cell* 64:671; Sanfacon *et al.* (1991) *Genes Dev.* 5:141; Mogen *et al.* (1990) *Plant Cell* 2:1261; Munroe *et al.* (1990) *Gene* 91:151; Ballas *et al.* (1989) *Nucleic Acids Res.* 17:7891; and Joshi *et al.* (1987) *Nucleic Acids Res.* 15:9627. Additional exemplary termination sequences are the pea RubP carboxylase small
20 subunit termination sequence and the Cauliflower Mosaic Virus 35S termination sequence. Other suitable termination sequences will be apparent to those skilled in the art.

Alternatively, the gene(s) of interest can be provided on any other suitable expression cassette known in the art.

25 The expression cassettes may contain more than one gene or nucleic acid sequence to be transferred and expressed in the transformed plant. Thus, each nucleic acid sequence will be operably linked to 5' and 3' regulatory sequences. Alternatively, multiple expression cassettes may be provided.

Generally, the expression cassette will comprise a selectable marker gene for
30 the selection of transformed cells or tissues. Selectable marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring

resistance to herbicidal compounds. Herbicide resistance genes generally code for a modified target protein insensitive to the herbicide or for an enzyme that degrades or detoxifies the herbicide in the plant before it can act. See DeBlock *et al.* (1987) *EMBO J.* 6:2513; DeBlock *et al.* (1989) *Plant Physiol.* 91:691; Fromm *et al.* (1990) *BioTechnology* 8:833; Gordon-Kamm *et al.* (1990) *Plant Cell* 2:603. For example, resistance to glyphosphate or sulfonylurea herbicides has been obtained using genes coding for the mutant target enzymes, 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) and acetolactate synthase (ALS). Resistance to glufosinate ammonium, boromoxynil, and 2,4-dichlorophenoxyacetate (2,4-D) have been obtained by using bacterial genes encoding phosphinothricin acetyltransferase, a nitrilase, or a 2,4-dichlorophenoxyacetate monooxygenase, which detoxify the respective herbicides.

For purposes of the present invention, selectable marker genes include, but are not limited to, genes encoding neomycin phosphotransferase II (Fraley *et al.* (1986) *CRC Critical Reviews in Plant Science* 4:1); cyanamide hydratase (Maier-Greiner *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:4250); aspartate kinase; dihydrodipicolinate synthase (Perl *et al.* (1993) *BioTechnology* 11:715); bar gene (Toki *et al.* (1992) *Plant Physiol.* 100:1503; Meagher *et al.* (1996) *Crop Sci.* 36:1367); tryptophan decarboxylase (Goddijn *et al.* (1993) *Plant Mol. Biol.* 22:907); neomycin phosphotransferase (NEO; Southern *et al.* (1982) *J. Mol. Appl. Gen.* 1:327); hygromycin phosphotransferase (HPT or HYG; Shimizu *et al.* (1986) *Mol. Cell. Biol.* 6:1074); dihydrofolate reductase (DHFR; Kwok *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:4552); phosphinothricin acetyltransferase (DeBlock *et al.* (1987) *EMBO J.* 6:2513); 2,2-dichloropropionic acid dehalogenase (Buchanan-Wollaston *et al.* (1989) *J. Cell. Biochem.* 13D:330); acetohydroxyacid synthase (U.S. Pat. No. 4,761,373 to Anderson *et al.*; Haughn *et al.* (1988) *Mol. Gen. Genet.* 221:266); 5-enolpyruvylshikimate-phosphate synthase (aroA; Comai *et al.* (1985) *Nature* 317:741); haloarylnitrilase (WO 87/04181 to Stalker *et al.*); acetyl-coenzyme A carboxylase (Parker *et al.* (1990) *Plant Physiol.* 92:1220); dihydropteroate synthase (sulf; Guerineau *et al.* (1990) *Plant Mol. Biol.* 15:127); and 32 kDa photosystem II polypeptide (psbA; Hirschberg *et al.* (1983) *Science* 222:1346 (1983).

Also included are genes encoding resistance to: gentamycin (*e.g.*, aacC1, Wohlleben *et al.* (1989) *Mol. Gen. Genet.* 217:202-208); chloramphenicol (Herrera-

Estrella *et al.* (1983) *EMBO J.* 2:987); methotrexate (Herrera-Estrella *et al.* (1983) *Nature* 303:209; Meijer *et al.* (1991) *Plant Mol. Biol.* 16:807); hygromycin (Waldron *et al.* (1985) *Plant Mol. Biol.* 5:103; Zhijian *et al.* (1995) *Plant Science* 108:219; Meijer *et al.* (1991) *Plant Mol. Bio.* 16:807); streptomycin (Jones *et al.* (1987) *Mol.*
 5 *Gen. Genet.* 210:86); spectinomycin (Bretagne-Sagnard *et al.* (1996) *Transgenic Res.* 5:131); bleomycin (Hille *et al.* (1986) *Plant Mol. Biol.* 7:171); sulfonamide (Guerineau *et al.* (1990) *Plant Mol. Bio.* 15:127); bromoxynil (Stalker *et al.* (1988) *Science* 242:419); 2,4-D (Streber *et al.* (1989) *BioTechnology* 7:811); phosphinothricin (DeBlock *et al.* (1987) *EMBO J.* 6:2513); spectinomycin (Bretagne-
 10 Sagnard and Chupeau, *Transgenic Research* 5:131).

The bar gene confers herbicide resistance to glufosinate-type herbicides, such as phosphinothricin (PPT) or bialaphos, and the like. As noted above, other selectable markers that could be used in the vector constructs include, but are not limited to, the pat gene, also for bialaphos and phosphinothricin resistance, the ALS gene for
 15 imidazolinone resistance, the HPH or HYG gene for hygromycin resistance, the EPSP synthase gene for glyphosate resistance, the Hm1 gene for resistance to the Hc-toxin, and other selective agents used routinely and known to one of ordinary skill in the art. See Yarranton (1992) *Curr. Opin. Biotech.* 3:506; Chistopherson *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:6314; Yao *et al.* (1992) *Cell* 71:63; Reznikoff (1992) *Mol.*
 20 *Microbiol.* 6:2419; Barkley *et al.* (1980) *The Operon* 177-220; Hu *et al.* (1987) *Cell* 48:555; Brown *et al.* (1987) *Cell* 49:603; Figge *et al.* (1988) *Cell* 52:713; Deuschle *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:5400; Fuerst *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:2549; Deuschle *et al.* (1990) *Science* 248:480; Labow *et al.* (1990) *Mol. Cell. Biol.* 10:3343; Zambretti *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3952; Baim
 25 *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:5072; Wyborski *et al.* (1991) *Nuc. Acids Res.* 19:4647; Hillenand-Wissman (1989) *Topics in Mol. And Struc. Biol.* 10:143; Degenkolb *et al.* (1991) *Antimicrob. Agents Chemother.* 35:1591; Kleinschmidt *et al.* (1988) *Biochemistry* 27:1094; Gatz *et al.* (1992) *Plant J.* 2:397; Gossen *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:5547; Oliva *et al.* (1992) *Antimicrob. Agents*
 30 *Chemother.* 36:913; Hlavka *et al.* (1985) *Handbook of Experimental Pharmacology* 78; and Gill *et al.* (1988) *Nature* 334:721. Such disclosures are herein incorporated by reference.

The above list of selectable marker genes are not meant to be limiting. Any selectable marker gene can be used in the present invention.

B. Modification of Nucleotide Sequences for Enhanced Expression in Duckweed

5 The present invention provides for the modification of the expressed nucleotide sequence to enhance its expression in duckweed. One such modification is the synthesis of the nucleotide sequence of interest using duckweed-preferred codons. Methods are available in the art for synthesizing nucleotide sequences with plant-preferred codons. See, e.g., U.S. Patent Nos. 5,380,831 and 5,436,391; Perlak *et al.* 10 (1991) *Proc. Natl. Acad. Sci. USA* 15:3324; Iannacome *et al.* (1997) *Plant Mol. Biol.* 34:485; and Murray *et al.*, (1989) *Nucleic Acids. Res.* 17:477, herein incorporated by reference. The preferred codons may be determined from the codons of highest frequency in the proteins expressed in duckweed. For example, the frequency of codon usage for *Lemna gibba* is found on the web page:

15 [http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+\[gbpln\]](http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+[gbpln]), and the frequency of codon usage for *Lemna minor* is found on the web page [http://www.kazusa.or.jp/codon/cgibin/showcodon.cgi?species=Lemna+minor+\[gbpln\]](http://www.kazusa.or.jp/codon/cgibin/showcodon.cgi?species=Lemna+minor+[gbpln]). It is recognized that genes which have been optimized for expression in duckweed and other monocots can be used in the methods of the 20 invention. See, e.g., EP 0 359 472, EP 0 385 962, WO 91/16432; Perlak *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:3324; Iannacome *et al.* (1997) *Plant Mol. Biol.* 34:485; and Murray *et al.* (1989) *Nuc. Acids Res.* 17:477, and the like, herein incorporated by reference. It is further recognized that all or any part of the gene sequence may be optimized or synthetic. In other words, fully optimized or partially optimized 25 sequences may also be used. For example, 40 %, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the codons may be duckweed-preferred codons. In one embodiment, between 90 and 96 % of the codons are duckweed-preferred codons. The coding sequence of the nucleotide sequence of interest may comprise codons used with a 30 frequency of at least 17% in *Lemna gibba*. In one embodiment, the modified nucleotide sequence is the human α -2B-interferon encoding nucleotide sequence shown in SEQ ID NO:2, which contains 93% duckweed preferred codons.

Other modifications can also be made to the nucleotide sequence of interest to enhance its expression in duckweed. These modifications include, but are not limited to, elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well characterized sequences which may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence may be modified to avoid predicted hairpin secondary mRNA structures.

There are known differences between the optimal translation initiation context nucleotide sequences for translation initiation codons in animals and plants and the composition of these translation initiation context nucleotide sequence can influence the efficiency of translation initiation. See, for example, Lukaszewicz *et al.* (2000) *Plant Science* 154:89-98; and Joshi *et al.* (1997); *Plant Mol. Biol.* 35:993-1001. In the present invention, the translation initiation context nucleotide sequence for the translation initiation codon of the nucleotide sequence of interest may be modified to enhance expression in duckweed. In one embodiment, the nucleotide sequence is modified such that the three nucleotides directly upstream of the translation initiation codon of the nucleotide sequence of interest are "ACC." In a second embodiment, these nucleotides are "ACA."

Expression of a transgene in duckweed can also be enhanced by the use of 5' leader sequences. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include, but are not limited to, picornavirus leaders, e.g., EMCV leader (Encephalomyocarditis 5' noncoding region; Elroy-Stein *et al.* (1989) *Proc. Natl. Acad. Sci USA* 86:6126); potyvirus leaders, e.g., TEV leader (Tobacco Etch Virus; Allison *et al.* (1986) *Virology* 154:9); human immunoglobulin heavy-chain binding protein (BiP; Macajak and Sarnow (1991) *Nature* 353:90); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4; Jobling and Gehrke (1987) *Nature* 325:622); tobacco mosaic virus leader (TMV; Gallie (1989) *Molecular Biology of RNA*, 23:56); potato etch virus leader (Tomashevskaya *et al.* (1993) *J. Gen. Virol.* 74:2717-2724); Fed-1 5' untranslated region (Dickey (1992) *EMBO J.* 11:2311-2317); RbcS 5' untranslated region (Silverthorne *et al.* (1990) *J. Plant. Mol. Biol.* 15:49-58); and maize chlorotic mottle

virus leader (MCMV; Lommel *et al.* (1991) *Virology* 81:382). See also, Della-Cioppa *et al.* (1987) *Plant Physiology* 84:965. Leader sequence comprising plant intron sequence, including intron sequence from the maize dehydrogenase 1 gene, the castor bean catalase gene, or the Arabidopsis tryptophan pathway gene PAT1 has also
5 been shown to increase translational efficient in plants (Callis *et al.* (1987) *Genes Dev.* 1:1183-1200; Mascarenhas *et al.* (1990) *Plant Mol. Biol.* 15:913-920). In one embodiment of the present invention, nucleotide sequence corresponding to nucleotides 1222-1775 of the maize alcohol dehydrogenase 1 gene (GenBank Accession Number X04049), set forth in SEQ ID NO: 1, is inserted upstream of the
10 nucleotide sequence of interest to enhance the efficiency of its translation.

It is recognized that any of the duckweed expression-enhancing nucleotide sequence modifications described above can be used in the present invention, including any single modification or any possible combination of modifications. The phrase "modified for enhanced expression in duckweed" as used herein refers to a
15 nucleotide sequence that contains any one or any combination of these modifications.

C. Signal Peptides

Secreted proteins are usually translated from precursor polypeptides that include a "signal peptide" that interacts with a receptor protein on the membrane of
20 the endoplasmic reticulum (ER) to direct the translocation of the growing polypeptide chain across the membrane and into the endoplasmic reticulum for secretion from the cell. This signal peptide is often cleaved from the precursor polypeptide to produce a "mature" polypeptide lacking the signal peptide. In an embodiment of the present invention, a biologically active polypeptide is expressed in duckweed from a
25 nucleotide sequence that is operably linked with a nucleotide sequence encoding a signal peptide that directs secretion of the polypeptide into the culture medium. Plant signal peptides that target protein translocation to the endoplasmic reticulum (for secretion outside of the cell) are known in the art. See, for example, U.S. Patent No. 6,020,169 to Lee *et al.* In the present invention, any plant signal peptide can be used
30 to in target polypeptide expression to the ER. In some embodiments, the signal peptide is the *Arabidopsis thaliana* basic endochitinase signal peptide (SEQ ID NO:8; amino acids 14-34 of NCBI Protein Accession No. BAA82823), the extensin signal

peptide (Stiefel *et al.* (1990) *Plant Cell* 2:785-793), the rice α -amylase signal peptide (SEQ ID NO:6; amino acids 1-31 of NCBI Protein Accession No. AAA33885), or a modified rice α -amylase signal sequence (SEQ ID NO:7). In another embodiment, the signal peptide corresponds to the signal peptide of a secreted duckweed protein.

5 Alternatively, a mammalian signal peptide can be used to target recombinant polypeptides expressed in genetically engineered duckweed for secretion. It has been demonstrated that plant cells recognize mammalian signal peptides that target the endoplasmic reticulum, and that these signal peptides can direct the secretion of polypeptides not only through the plasma membrane but also through the plant cell
10 wall. See U.S. Patent Nos. 5,202,422 and 5,639,947 to Hiatt *et al.* In one embodiment of the present invention, the mammalian signal peptide that targets polypeptide secretion is the human α -2b-interferon signal peptide (amino acids 1-23 of NCBI Protein Accession No. AAB59402 and SEQ ID NO:4).

 In one embodiment, the nucleotide sequence encoding the signal peptide is
15 modified for enhanced expression in duckweed, utilizing any modification or combination of modifications disclosed in section B above for the nucleotide sequence of interest. In another embodiment, the signal peptide the rice α -amylase encoded by the modified nucleotide sequence set forth in SEQ ID NO:3, which contains approximately 93% duckweed preferred codons.

20 The secreted biologically active polypeptide can be harvested from the culture medium by any conventional means known in the art and purified by chromatography, electrophoresis, dialysis, solvent-solvent extraction, and the like.

D. Transformed Duckweed Plants and Duckweed Nodule Cultures

25 The stably transformed duckweed utilized in this invention can be obtained by any method known in the art. In one embodiment, the stably transformed duckweed is obtained by one of the gene transfer methods disclosed in U.S. Patent No. 6,040,498 to Stomp *et al.*, herein incorporated by reference. These methods include gene transfer by ballistic bombardment with microprojectiles coated with a nucleic
30 acid comprising the nucleotide sequence of interest, gene transfer by electroporation, and gene transfer mediated by *Agrobacterium* comprising a vector comprising the nucleotide sequence of interest. In one embodiment, the stably transformed

duckweed is obtained via any one of the *Agrobacterium*-mediated methods disclosed in U.S. Patent No. 6,040,498 to Stomp *et al.* The *Agrobacterium* used is *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes*.

It is preferred that the stably transformed duckweed plants utilized in these methods exhibit normal morphology and are fertile by sexual reproduction. Preferably, transformed plants of the present invention contain a single copy of the transferred nucleic acid, and the transferred nucleic acid has no notable rearrangements therein. Also preferred are duckweed plants in which the transferred nucleic acid is present in low copy numbers (i.e., no more than five copies, alternately, no more than three copies, as a further alternative, fewer than three copies of the nucleic acid per transformed cell).

The stably transformed duckweed expresses a biologically active protein hormone, growth factor, or cytokine, insulin, or growth hormone (in particular, human growth hormone). Alternatively, the duckweed expresses biologically active β -glucuronidase. The duckweed may express biologically active α -2b-interferon, for example human α -2b-interferon precursor (NCBI Protein Accession No. AAB59402; set forth in SEQ ID NO:4) or mature human α -2b-interferon (amino acids 24-188 of NCBI Protein Accession No. AAB9402; set forth in SEQ ID NO:5) or biologically active variants thereof.

By "biologically active variant" of human α -2b-interferon is intended a polypeptide derived from the native polypeptide by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Biologically active variant α -2b-interferon polypeptides encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native α -2b-interferon including the ability to increase resistance to viral infection, or the ability to modulate the transcription of α -2b-interferon-regulated gene targets. Such biologically active variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native α -2b-interferon protein of the

invention will have at least about 50%, 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:5. Thus, a biologically active
5 variant of an α -2b-interferon of the invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue. Examples of biologically active variants of human α -interferon are known in the art. See, for example, European patent EP211148B1, and U.S. Patent Nos. 4,748,233, 4,801,685, 4,816,566, 4,973,479, 4,975,276,
10 5,089,400, 5,098,703, 5,231,176, and 5,869,293; herein incorporated by reference.

The comparison of sequences and determination of percent identity and percent similarity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (1970) *J. Mol. Biol.*
15 48:444-453 algorithm, which is incorporated into the GAP program in the GCG software package (available at www.accelrys.com), using either a BLOSSUM62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG
20 software package, using a BLOSUM62 scoring matrix (see Henikoff *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used if the practitioner is uncertain about what parameters should be applied to determine if a molecule is within a sequence identity limitation of the
25 invention) is using a BLOSUM62 scoring matrix with a gap weight of 60 and a length weight of 3).

The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller (1989) *CABIOS* 4:11-17 which has been incorporated into the ALIGN program (version 2.0), using a
30 PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

In one embodiment, the stably transformed duckweed plants or duckweed nodule cultures express biologically active polypeptides that cannot effectively be

commercially produced by existing gene expression systems, because of cost or logistical constraints, or both. For example, some proteins cannot be expressed in mammalian systems because the protein interferes with cell viability, cell proliferation, cellular differentiation, or protein assembly in mammalian cells. Such proteins include, but are not limited to, retinoblastoma protein, p53, angiostatin, and leptin. The present invention can be advantageously employed to produce mammalian regulatory proteins; it is unlikely given the large evolutionary distance between higher plants and mammals that these proteins will interfere with regulatory processes in duckweed. Transgenic duckweed can also be used to produce large quantities of proteins such as serum albumin (in particular, human serum albumin), hemoglobin, and collagen, which challenge the production capabilities of existing expression systems.

Finally, higher plant systems can be engineered to produce biologically active multimeric proteins (e.g., monoclonal antibodies, hemoglobin, P450 oxidase, and collagen, and the like) far more easily than can mammalian systems. One exemplary approach for producing biologically active multimeric proteins in duckweed uses an expression vector containing the genes encoding all of the polypeptide subunits. See, e.g., During *et al.* (1990) *Plant Mol. Biol.* 15:281 and van Engelen *et al.* (1994) *Plant Mol. Biol.* 26:1701. This vector is then introduced into duckweed cells using any known transformation method, such as a ballistic bombardment or *Agrobacterium*-mediated transformation. This method results in clonal cell lines that express all of the polypeptides necessary to assemble the multimeric protein. A variation on this approach is to make single gene constructs, mix DNA from these constructs together, then deliver this mixture of DNAs into plant cells using ballistic bombardment or *Agrobacterium*-mediated transformation. As a further variation, some or all of the vectors may encode more than one subunit of the multimeric protein (i.e., so that there are fewer duckweed clones to be crossed than the number of subunits in the multimeric protein). In an alternative embodiment, each duckweed clone expresses at least one of the subunits of the multimeric protein, and duckweed clones secreting each subunit are cultured together and the multimeric protein is assembled in the media from the various secreted subunits. In some instances, it may be desirable to produce less than all of the subunits of a multimeric protein, or even a single protein

subunit, in a transformed duckweed plant or duckweed nodule culture, e.g., for industrial or chemical processes or for diagnostic, therapeutic, or vaccination purposes.

5

EXPERIMENTAL

The following examples are offered for purposes of illustration, not by way of limitation.

10 Expression Vectors

The expression vector pBMSP-1 used in some of the examples is described in U.S. Patent No. 5,955,646, herein incorporated by reference. The pBMSP-1 transcriptional cassette contains three copies of a transcriptional activating nucleotide sequence derived from the *Agrobacterium tumefaciens* octopine synthase and, an
15 additional transcriptional activating nucleotide sequence derived from the *Agrobacterium tumefaciens* mannopine synthase gene, a promoter region derived from the *Agrobacterium tumefaciens* mannopine synthase gene, a polylinker site for insertion of the nucleotide sequence encoding the polypeptide of interest, and a
20 termination sequence derived from the *Agrobacterium tumefaciens* nopaline synthase gene. The pBMSP-1 expression vector also contains a nucleotide sequence coding for neomycin phosphotransferase II as a selectable marker. Transcription of the selectable marker sequence is driven by a promoter derived from the *Agrobacterium tumefaciens* nopaline synthase gene.

The expression vector pBMSP-3, also used in some of the following
25 examples, contains the components of the pBMSP-1 expression vector described above and additionally contains a nucleotide sequence corresponding to nucleotides 1222-1775 of the maize alcohol dehydrogenase gene (GenBank Accession Number X04049) inserted between the promoter and the polylinker.

Expression Constructs for the Production of Human α -2b-Interferon in Duckweed

The following expression constructs were constructed using methods well known in the art. See, for example, Sambrook, J., Fritsh, E. F., and Maniatis, T.

Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory,

5 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

Table 1

Construct Name	Expression Vector	Signal Peptide	Interferon-encoding Sequence
IFN01	pBMSP-1	None	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN02	pBMSP-3	Non-optimized interferon (nucleotides 511-579 of GenBank Accession No. J00207)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN03	pBMSP-3	<i>Arabidopsis thaliana</i> endochitinase (nucleotides 338-399 of GenBank Accession number AB023460 with an additional "A" added to the 3' end of the sequence)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN05	pBMSP-3	Modified rice α -amylase * (encoding the amino acid sequence shown in SEQ ID NO:7)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN07	pBMSP-3	Wild type rice α -amylase (nucleotides 34-126 of GenBank Accession No. M24286, encoding the amino acid sequence shown in SEQ ID NO:6)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN08	pBMSP-3	Optimized wild type rice α -amylase (SEQ ID NO:3)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN09	pBMSP-3	Optimized wild type rice α -amylase (SEQ ID NO:3)	Optimized interferon (SEQ ID NO:2)
IFN10	pBMSP-3	None	Optimized interferon (SEQ ID NO:2)
IFN11	pBMSP-1	Optimized wild type rice α -amylase (SEQ ID NO:3)	Optimized interferon (SEQ ID NO:2)
IFN12	pBMSP-1	None	Optimized interferon (SEQ ID NO:2)

*The nucleotide sequence encoding the modified rice α -amylase signal peptide corresponds to nucleotides 34-126 of GenBank Accession No. M24286, except that nucleotides 97-102 have been changed from "CTTGGC" to "ATCGTC."

5 Transformation of Duckweed

Duckweed fronds or duckweed nodule cultures (derived from *Lemna minor* strain 8627 in these examples) are transformed with the expression constructs described above using Agrobacteria-mediated transformation methods.

- Agrobacterium tumefaciens* strain C58Z707, a disarmed, broad host range C58 strain (Hepburn *et al.* (1985) *J. Gen. Microbiol.* 131:2961-2969) is used for transformation in these examples. The expression constructs described above are mobilized into *A. tumefaciens* by electroporation, or by a triparental mating procedure using *E. coli* MM294 harboring the mobilizing plasmid pRK2013 (Hoekema *et al.* (1983) *Nature* 303: 179-180; Ditta *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77: 7347-7350).
- C58Z707 strains comprising the expression constructs described above are streaked on AB minimal medium (Chilton *et al.*, (1974) *Proc. Nat. Acad. Sci. USA* 71: 3672 - 3676) or in YEB medium (1 g/L yeast extract, 5 g/L beef extract, 5 g/L peptone, 5 g/L sucrose, 0.5 g/L $MgSO_4$) containing streptomycin at 500 mg/L, spectinomycin at 50 mg/L and kanamycin sulfate at 50 mg/L and grown overnight at 28° C.
- In these examples, *Lemna minor* strain 8627 is used for transformation although any *Lemna* strain can be used. Fronds are grown on liquid Schenk and Hildebrandt medium (Schenk and Hildebrandt (1972) *Can. J. Bot.* 50:199) containing 1% sucrose and 10 μ M indoleacetic acid at 23° C. under a 16 hour light/8 hour dark photoperiod with light intensity of approximately 40 μ M/m²·sec. For inoculation, individual fronds are separated from clumps and floated in inoculation media for approximately 2 to 20 minutes. The inoculating medium is Schenk and Hildebrandt medium (pH 5.6) supplemented with 0.6 M mannitol and 100 μ M acetosyringone, with the appropriate *Agrobacterium tumefaciens* strain comprising the expression construct present at a concentration of about 1 X 10⁹ cells/ml. These fronds are then transferred to Schenk and Hildebrandt medium (pH 5.6) containing 1% sucrose, 0.9%

agar, and 20 mg/L acetosyringone and are co-cultivated for 3 or 4 days in the dark at 23° C.

Following co-cultivation, the fronds are transferred for recovery to Schenk and Hildebrandt medium or Murashige and Skoog medium (Murashige and Skoog (1962) *Physiol. Plant.* 15:473) supplemented with 200 µg/ml kanamycin sulfate. Fronds are decontaminated from infecting *Agrobacteria* by transferring the infected tissue to fresh medium with antibiotic every 2-4 days. The fronds are incubated on this medium for approximately four weeks under conditions of low light (1-5 µM/m²-sec).

Duckweed nodule cultures for transformation are produced as follows.

- 10 Duckweed fronds are separated, the roots are cut off with a sterile scalpel, and the fronds are placed, ventral side down, on Murashige and Skoog medium (catalog number M-5519; Sigma Chemical Corporation, St. Louis, MO) pH 5.6, supplemented with 5 µM 2,4-dichlorophenoxyacetic acid, 0.5 µM 1-Phenyl-3(1,2,3-thiadiazol-5-yl) urea thidiazuron (Sigma P6186), 3% sucrose, 0.4 Difco Bacto-agar (Fisher Scientific),
15 and 0.15% Gelrite (Sigma). Fronds are grown for 5-6 weeks. At this time, the nodules (small, yellowish cell masses) appear, generally from the central part of the ventral side. This nodule tissue is detached from the mother frond and cultured in Murashige and Skoog medium supplemented with 3% sucrose, 0.4% Difco Bacto-agar, 0.15% Gelrite, 1 µM 2,4-dichlorophenoxyacetic acid, and 2 µM benzyladenine.

- 20 Duckweed nodule cultures are transformed as follows. The appropriate *Agrobacterium tumefaciens* strain is grown on potato dextrose agar or YEB agar with 50 mg/L kanamycin and 100 µM acetosyringone, and resuspended in Murashige and Skoog medium supplemented with 0.6 M Mannitol and 100 µM acetosyringone. Nodule culture tissue is inoculated by immersing in the solution of resuspended
25 bacteria for 1-2 minutes, blotted to remove excess fluid, and plated on co-cultivation medium consisting of Murashige and Skoog medium supplemented with auxin and cytokinin optimized to promote nodule growth and 100 µM acetosyringone.

- For selection, nodule culture tissue is transferred to regeneration medium Murashige and Skoog medium with 3% sucrose, 1 µM 2,4-dichlorophenoxyacetate, 2
30 µM benzyladenine, 0.4 % Difco Bacto-Agar, 0.15% Gelrite 500 mg/L cefotaxime, and 200 mg/L kanamycin sulfate and cultured for approximately four weeks under

continuous light (20-40 $\mu\text{M}/\text{m}^2\cdot\text{sec}$). The nodule tissue is transferred every 7 days to fresh culture medium. Selection is complete when the nodule tissue shows vigorous growth on the selection agent. In some examples, the transformed duckweed nodule cultures are transferred directly to regeneration medium for selection, instead of
5 undergoing selection in co-cultivation medium.

For regeneration of transformed duckweed, the selected nodule culture is transferred to regeneration medium (0.5 X Schenk and Hildebrandt medium supplemented with 1% sucrose and 200 mgs/L kanamycin) to organize and produce plants. The nodule culture is incubated on regeneration medium under full light for
10 approximately 3 weeks, until fronds appear. Fully organized fronds are transferred to liquid Schenk and Hildebrandt medium with 1-3% sucrose and incubated under full light for further clonal proliferation.

Detection of Biologically-Active Interferon Produced from Duckweed Fronds or 15 Duckweed Nodule Culture

Biologically-active interferon is detected by various assays, including a solid phase sandwich immunoassay as described in Staehlin *et al.* (1981) *Methods Enzymol.* 79:589-594 and Kelder *et al.* (1986) *Methods Enzymol.* 119:582-587, herein incorporated by reference, and a cytopathic effect inhibition assay (described in
20 Tovey *et al.* (1978) *Nature* 276:270-272, herein incorporated by reference. Secreted interferon is collected from the duckweed culture medium, while non-secreted interferon is collected from ground-up or lysed duckweed plants or duckweed nodule tissue.

The solid phase sandwich immunoassay for interferon is performed using a kit
25 from PBL Laboratories (New Brunswick, NJ) according to the manufacturer's instructions. Briefly, interferon is captured by an antibody bound to the microtiter plate wells. A second antibody is then used to reveal the bound antibody. An anti-secondary antibody conjugated to horseradish peroxidase (HRP) is then used to mark the interferon. Tetramethyl benzidine (TMB) initiates a peroxidase-catalyzed color
30 change so that the interferon level can be observed and compared with a standard. A monoclonal antibody specific for α -2b-interferon (Cat. No. 11105, PBL Laboratories) is used for this assay in the present examples.

The cytopathic effect inhibition assay is performed according to the methods of Tovey *et al.* (1978) *Nature* 276:270-272. Briefly, serial two-fold dilutions of the preparation to be assayed are diluted in a 96 well microtiter plate (Falcon Inc) in a volume of 100 μ l of Eagles minimal essential medium (Life Technologies Inc) supplemented with 2 % fetal calf serum (Life Technologies Inc) in parallel with serial two fold dilutions of the US National Institutes of Health human IFN alpha international reference preparation (G-002-901-527). Twenty thousand human amnion cells (line WISH) are then added to each well of the microtiter plate in a volume of 100 μ l of medium with 2 % fetal calf serum. The cells are incubated over-night in an atmosphere of 5 % CO₂ in air at 37°C, the medium is removed and replaced with 200 μ l of medium with 2 % fetal calf serum containing vesicular stomatitis virus at a multiplicity of infection of 0.1. The cells are further incubated over-night in an atmosphere of 5 % CO₂ in air at 37 °C and the cytopathic effect due to virus replication is then evaluated under a light microscope. Interferons titers are expressed as the reciprocal of the IFN dilution which gave 50 % protection against the cytopathic effects of the virus. Interferon titers are expressed in international reference units by reference to the titer of the reference preparation.

The following examples demonstrate the expression of biologically active interferon in duckweed.

Example 1

A study was performed to determine culture IFN levels in media and tissue at various time points in a batch culture. A set of 20-30ml 175oz.-culture jars were inoculated on Day 0 with 20 fronds of a line previously identified as expressing detectable levels of human α -2b-interferon (IFN). The cultures were grown under autotrophic, buffered conditions with continuous high light provided by plant/aquarium fluorescent grow bulbs. At each time point - days 5, 7, 13, 15, and 18 – the fresh weight and media volume were measured for four cultures. From each culture, media and tissue samples were obtained and a plant protease inhibitor cocktail was added. The tissue samples were ground and spun cold. The supernatant was collected. Media and tissue extracts were stored at -70°C until all samples were collected. IFN levels in media and tissue extracts were determined on the same day

using the solid phase sandwich immunoassay described above. Total culture IFN in media and tissue was calculated by multiplying measured IFN concentrations and the volume of media and the fresh weight for the culture, respectively. Figure 1 shows the relative IFN levels on days 7, 13, 15, and 18 compared to day 5. The last time point represents the average value for three cultures instead of four due to loss of one culture.

Example 2

A study was performed to determine culture IFN levels in media and tissue at various time points in a batch culture. A set of 24-30ml 175oz.-culture jars were inoculated on Day 0 with 20 fronds same line as in Example 1. The cultures were grown under autotrophic, unbuffered conditions with continuous high light provided by plant/aquarium fluorescent grow bulbs. At each time point - days 7, 10, 12, 14, 17, and 19 - the fresh weight and media volume were measured for four cultures. From each culture, media and tissue samples were obtained and a plant protease inhibitor cocktail was added. The tissue samples were ground and spun cold. The supernatant was collected. Media and tissue extracts were stored at -70°C until all samples were collected. IFN levels in media and tissue extracts were determined on the same day using the solid phase sandwich immunoassay described above. Total culture IFN in media and tissue was calculated by multiplying measured IFN concentrations and the volume of media and the fresh weight for the culture, respectively. Figure 2 shows the relative IFN levels on days 14, 17, and 19 compared to day 12. Media IFN levels on day 7 and day 10 were below the range of the extended range protocol for the immunoassay.

25

Example 3

Duckweed lines transformed with the expression constructs listed in Table 1 were produced using the methods described above. These transformed duckweed lines were grown for 14 days under autotrophic conditions. Bovine serum albumin at a concentration of 0.2 mg/ml was included in the growth media. On day 14, media and tissue extracts were prepared as described in Example 1, and the interferon levels in these extracts were determined using the solid phase sandwich immunoassay as

described above. Table 2 gives the number of clonal duckweed lines assayed and the mean media interferon concentration for each expression construct. Table 3 shows the interferon levels within the duckweed tissue for the duckweed lines transformed with the interferon expression constructs that did not contain a signal peptide (IFN01, IFN10, and IFN12). Both the mean interferon level for all clonal lines assayed for the designated construct, and the interferon level for the top-expressing line are shown.

Table 2

Expression Construct	# of Clonal Lines	Mean Interferon
	Tested	Concentration (ng/ml)
IFN01	41	0
IFN02	75	2.3
IFN03	41	0.18
IFN05	44	2.5
IFN07	41	1.5
IFN08	41	1.4
IFN09	41	30.3
IFN10	41	0
IFN11	39	9.9
IFN12	41	0

Table 3

IFN Construct	Mean Value	Top Expresser
	% of total soluble protein	% of total soluble protein
IFN01	0.00003	0.0001
IFN10	0.00064	0.0074
IFN12	0.00014	0.001

The biological activity of the interferon produced by these transformed duckweed lines was assayed by the cytopathic effect inhibition assay described above. Table 4 gives the results for the top expressing line for each construct. The interferon

activity is shown for the media for those constructs containing a signal peptide and the tissue for those constructs lacking a signal peptide.

Table 4

IFN Construct	Top Expresser	
	Source material	IU/ml (media) IU/mg total protein (tissue)
IFN01	Tissue	40
IFN02	Media	16,000
IFN03	Media	320
IFN05	Media	6,400
IFN07	Media	6,000
IFN08	Media	3,200
IFN09	Media	200,000
IFN10	Tissue	19,300
IFN11	Media	30,000
IFN12	Tissue	150

5

The following features can be noted for the data in this example: (1) Secretion of interferon was detected only for those duckweed lines transformed with expression constructs containing a signal peptide. Compare, for example, the media interferon concentration for IFN02, IFN03, IFN05, IFN07, IFN08, IFN 09 and IFN011 with that for IFN01, IFN10, and IFN12. (2) Secretion of interferon was detected for all expression constructs containing a signal peptide, with the native human interferon signal sequence producing the highest level of secreted interferon. Compare, for example, the interferon levels produced by IFN02 with those produced by IFN03 and IFN05. (3) The use of duckweed-preferred codons leads to enhanced interferon expression. Compare, for example, the interferon levels produced by IFN09 with those for IFN05. (4) Higher expression levels were achieved by the codon optimization of more than just the signal peptide. Compare, for example, IFN08 with IFN09. (5) Including the maize alcohol dehydrogenase intron sequence in the expression construct resulted in higher levels of interferon expression. Compare, for example, IFN09 with IFN11 and IFN10 with IFN12. (6) No statistically significant difference was observed between the interferon levels expressed from the construct

containing the modified α -amylase signal peptide (IFN05) in comparison with that containing the wild-type alpha amylase signal peptide (IFN07).

5 All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method of producing a biologically active recombinant polypeptide in a duckweed plant culture or a duckweed nodule culture, comprising the steps of:
- 5 (a) culturing within a duckweed culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is expressed from a nucleotide sequence comprising a coding sequence
- 10 for the polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the polypeptide into the culture medium; and
- (b) collecting said biologically active polypeptide from the duckweed culture medium.
- 15 2. The method of claim 1, wherein said biologically active recombinant polypeptide is secreted into the duckweed culture medium.
3. The method of claim 1, wherein said nucleotide sequence has at least one attribute selected from the group consisting of:
- 20 (a) duckweed-preferred codons in the coding sequence for said polypeptide;
- (b) duckweed-preferred codons in the coding sequence for said signal peptide;
- (c) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and
- 25 (d) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence.
4. The method according to claim 3, wherein said duckweed-preferred codons are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons..
- 30

5. The method according to claim 4, wherein at least one coding sequence selected from the coding sequence for said polypeptide and the coding sequence for said signal peptide comprises between 70-100 % *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons..

6. The method according to claim 3, wherein said plant-preferred translation initiation context nucleotide sequence consists of the nucleotide sequence "ACC" or "ACA", wherein said context is positioned immediately adjacent to of the 5' end of the translation initiation codon.

7. The method according to claim 3, wherein said operably linked nucleotide sequence comprising said plant intron is the sequence set forth in SEQ ID NO:1.

8. A method of producing a biologically active recombinant polypeptide, comprising the steps of:

(a) culturing a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is encoded by a nucleotide sequence that has been modified for enhanced expression in duckweed, and

(b) collecting said biologically active polypeptide from said duckweed plant culture or said duckweed nodule culture.

9. The method of claim 8, wherein said nucleotide sequence that has been modified for enhanced expression in duckweed has at least one attribute selected from the group consisting of:

(a) duckweed-preferred codons in the coding sequence for said biologically active recombinant polypeptide;

(b) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and

(c) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence.

10. The method according to claim 9, wherein said duckweed-preferred
5 codons are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons.

11. The method according to claim 10, wherein the coding sequence
comprises between 70% and 100% *Lemna gibba*-preferred codons or *Lemna minor*-
preferred codons.

10

12. The method according to claim 9, wherein said plant-preferred
translation initiation context nucleotide sequence consists of the nucleotide sequence
"ACC" or "ACA", wherein said context is positioned immediately adjacent to the 5'
end of the translation initiation codon.

15

13. The method according to claim 9, wherein said operably linked
nucleotide sequence comprising said plant intron is the sequence set forth in SEQ ID
NO:1.

20 14. The method according to claim 1, wherein said duckweed frond culture
or duckweed nodule culture expresses and assembles all of the subunits of a
biologically active multimeric protein.

15. The method according to claim 14, wherein said biologically active
25 multimeric protein is selected from the group consisting of collagen, hemoglobin,
P450 oxidase, and a monoclonal antibody.

16. The method according to claim 1, wherein the biologically active
recombinant polypeptide is a mammalian polypeptide.

30

17. The method according to claim 16, wherein the mammalian
polypeptide is a therapeutic polypeptide.

18. The method according to claim 16, wherein the mammalian polypeptide is selected from the group consisting of insulin, growth hormone, α -interferon, β -interferon, β -glucocerebrosidase, β -glucuronidase, retinoblastoma protein, p53 protein, angiostatin, leptin, monoclonal antibodies, cytokines, receptors, human vaccines, animal vaccines, plant polypeptides, and serum albumin.

19. The method according to claim 1, wherein the biologically active recombinant polypeptide is α -2b-interferon.

20. The method according to claim 19, wherein said α -2b-interferon is human α -2b-interferon.

21. The method according to claim 20, wherein said human α -2b-interferon has the amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:5.

22. The method according to claim 1, wherein the biologically active recombinant polypeptide is a biologically active variant of α -2b-interferon, wherein said biologically active variant has at least 80% sequence identity with SEQ ID NO:4 or SEQ ID NO:5.

23. The method according to claim 1, wherein the biologically active recombinant polypeptide is an enzyme.

24. The method according to claim 1, wherein said signal peptide sequence is selected from the group consisting of:

- (a) the human α -2b-interferon signal peptide;
- (b) the *Arabidopsis thaliana* chitinase signal peptide;
- (c) the rice α -amylase signal peptide;
- (d) the modified rice α -amylase peptide;
- (e) a duckweed signal peptide; and

(f) a signal peptide native to the biologically active recombinant polypeptide.

25. The method according to claim 24, wherein the signal peptide is the rice α -amylase signal peptide having the sequence set forth in SEQ ID NO:3.

26. The stably transformed duckweed plant culture or duckweed nodule culture according to claim 1.

27. The stably transformed duckweed plant culture or duckweed nodule culture according to claim 26, wherein said duckweed plant culture or duckweed nodule culture is selected from the group consisting of the genus *Spirodela*, genus *Wolffia*, genus *Wolffiella*, and genus *Lemna*.

28. The stably transformed duckweed plant culture or duckweed nodule culture according to claim 27, wherein said duckweed plant culture or duckweed nodule culture is selected from the group consisting of *Lemna minor*, *Lemna miniscula*, *Lemna aequinotialis*, and *Lemna gibba*.

29. A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence set forth in SEQ ID NO:4;
- (b) the amino acid sequence set forth in SEQ ID NO:5;
- (c) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:4, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:4; and
- (d) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:5, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:5;

wherein said nucleotide sequence comprises duckweed-preferred codons.

30. The nucleic acid molecule of claim 29, wherein said nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO: 2.

5 31. A nucleic acid molecule comprising a nucleotide sequence encoding a signal peptide selected from the group consisting of:

(a) the rice α -amylase signal peptide amino acid sequence set forth in SEQ ID NO:6; and

(b) the modified rice-amylase signal peptide amino acid sequence
10 set forth in SEQ ID NO:7;
wherein said nucleotide sequence comprises duckweed-preferred codons.

32. The nucleic acid molecule of claim 31, wherein said nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO: 3.

15 33. A nucleic acid molecule of claim 29, wherein said nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:5 and further comprises the signal peptide-encoding nucleotide sequence given in SEQ ID NO:3, and said nucleotide sequence set forth in SEQ ID NO:5 and said signal peptide-
20 encoding nucleotide sequence given in SEQ ID NO:3 are operably linked.

34. The nucleic acid molecule of claim 33, additionally comprising the intron-comprising nucleotide sequence given in SEQ ID NO:1, wherein said intron-comprising nucleotide sequence, said signal peptide-encoding nucleotide sequence
25 and said mature human α -2b-interferon-encoding nucleotide sequence are operably linked.

Example 1: Relative IFN Levels in Tissue and Media




FIGURE 1

2/2

Example 2: Relative IFN Levels In Media and Tissue




FIGURE 2

SEQUENCE LISTING

<110> Bioplex, Inc.
Stomp, Anne-Marie
Dickey, Lynn
Gasdaska, John

<120> Expression of Biologically Active
Polypeptides in Duckweed

<130> 40989/237187

<150> US 60/293,330

<151> 2001-05-23

<150> US 60/221,705

<151> 2000-07-31

<160> 8

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 554

<212> DNA

<213> Zea mays

<400> 1

```

gatcaagtgc aaaggtccgc cttgtttctc ctctgtctct tgatctgact aatcttggtt 60
tatgattcgt tgagtaattt tggggaaagc ttcgtccaca gttttttttt cgatgaacag 120
tgccgcagtg gcgctgatct tgtatgctat cctgcaatcg tggatgaactt atgtctttta 180
tattccttcac taccatgaaa agactagtaa tctttctoga tgtaacatcg tccagcactg 240
ctattaccgt gtggtccatc cgacagtctg gctgaacaca tcatacgata ttgagcaaag 300
atctatcttc cctgtttctt aatgaaagac gtcattttca tcagtatgat ctaagaatgt 360
tgcaacttgc aaggaggcgt ttctttcttt gaatttaact aactcgttga gtggccctgt 420
ttctcggacg taaggccctt gctgctccac acatgtccat tcgaatttta ccgtgtttag 480
caagggcgaa aagtttgcct cttgatgatt tagcttgact atgcgattgc ttccctggac 540
ccgtgcagct gcgg

```

<210> 2

<211> 498

<212> DNA

<213> Artificial Sequence

<220>

<223> Duckweed codon optimized nucleotide sequence
encoding human alpha-2B interferon

<221> CDS

<222> (1)...(498)

<400> 2

```

tgc gac ctc ccc cag acc cac agc ctc ggg tcc cgc cgc acc ctc atg 48
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
1 5 10 15

ctg ctg gcg cag atg cgc cgc atc tcg ctc ttc agc tgc ctg aag gac 96
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30

cgc cac gac ttc ggc ttc ccg cag gag gag ttc ggc aac cag ttc cag 144
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
35 40 45

```

```

aag gcc gag acg atc ccc gtg ctc cac gag atg atc cag cag atc ttc 192
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
    50                55                60

aac ctg ttc agc acc aag gac agc tcg gcc gcc tgg gac gag acc ctg 240
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
    65                70                75                80

ctc gac aag ttc tac acc gag ctg tac cag cag ctc aac gac ctg gag 288
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
                85                90                95

gcg tgc gtg atc cag ggg gtt ggg gtt acg gag acg ccg ctg atg aag 336
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                100                105                110

gag gac agc atc ctc gcc gtg cgc aag tac ttc cag cgc atc acg ctc 384
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                115                120                125

tac ctc aag gag aag aag tac agc ccg tgc gcc tgg gag gtc gtt cgc 432
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
                130                135                140

gcc gag atc atg cgc tcc ttc agc ctg agc acc aac ctc cag gag agc 480
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
    145                150                155                160

ctc cgc tcc aag gag taa 498
Leu Arg Ser Lys Glu *
                165

```

<210> 3
 <211> 96
 <212> DNA
 <213> Oryza sativa

```

<400> 3
accatgcagg tcctgaacac gatggtaaac aagcacttcc tctccctgtc cgctcctcatc 60
gtcctcctcg ggctgagcag caacctcacc gccggc 96

```

<210> 4
 <211> 188
 <212> PRT
 <213> Homo sapiens

```

<400> 4
Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu Val Leu Ser Cys
 1      5      10      15
Lys Ser Ser Cys Ser Val Gly Cys Asp Leu Pro Gln Thr His Ser Leu
    20      25      30
Gly Ser Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser
    35      40      45
Leu Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu
    50      55      60
Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His
    65      70      75      80
Glu Met Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser
    85      90      95
Ala Ala Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr
    100      105      110
Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val
    115      120      125

```

```

Thr Glu Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys
  130          135          140
Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro
  145          150          155          160
Cys Ala Trp Glu Val Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu
          165          170          175
Ser Thr Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu
          180          185

```

<210> 5
 <211> 165
 <212> PRT
 <213> Homo sapiens

```

<400> 5
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
  1          5          10          15
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
  20          25          30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
  35          40          45
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
  50          55          60
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
  65          70          75          80
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
          85          90          95
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
  100          105          110
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
  115          120          125
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
  130          135          140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
  145          150          155          160
Leu Arg Ser Lys Glu
          165

```

<210> 6
 <211> 31
 <212> PRT
 <213> Oryza sativa

```

<400> 6
Met Gln Val Leu Asn Thr Met Val Asn Lys His Phe Leu Ser Leu Ser
  1          5          10          15
Val Leu Ile Val Leu Leu Gly Leu Ser Ser Asn Leu Thr Ala Gly
          20          25          30

```

<210> 7
 <211> 31
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Modified rice alpha-amylase signal peptide

```

<400> 7
Met Gln Val Leu Asn Thr Met Val Asn Lys His Phe Leu Ser Leu Ser
  1          5          10          15
Val Leu Ile Val Leu Thr Val Leu Ser Ser Asn Leu Thr Ala Gly
          20          25          30

```

<210> 8
<211> 21
<212> PRT
<213> Arabidopsis thaliana

<400> 8
Met Lys Thr Asn Leu Phe Leu Phe Leu Ile Phe Ser Leu Leu Leu Ser
1 5 10 15
Leu Ser Ser Ala Glu
20

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/010414 A3

(51) International Patent Classification⁷: **C12N 15/82**,
15/67, 15/62, C07K 14/56

Buckden Place, Cary, NC 27511 (US). **GASDASKA, John** [US/US]; 102 Lisa Drive, Carrboro, NC 27510 (US).

(21) International Application Number: PCT/US01/23400

(74) Agents: **COULTER, Kathryn, L.** et al.; Alston & Bird LLP, Bank of America Plaza, Suite 4000, 101 South Tryon Street, Charlotte, NC 28280-4000 (US).

(22) International Filing Date: 26 July 2001 (26.07.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
60/221,705 31 July 2000 (31.07.2000) US
60/293,330 23 May 2001 (23.05.2001) US

(71) Applicant (*for all designated States except US*): **BIOLEX, INC.** [US/US]; 158 Credle Street, Pittsboro, NC 27312 (US).


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **STOMP, Anne-Marie** [US/US]; 565 East River Road, Moncure, NC 27559 (US). **DICKEY, Lynn** [US/US]; 111

[Continued on next page]

(54) Title: EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES IN DUCKWEED

EXAMPLE 1: RELATIVE IFN LEVELS IN TISSUE AND MEDIA



(57) Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.

WO 02/010414 A3



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

27 December 2002

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23400

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N15/67 C12N15/62 C07K14/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CAB Data, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 07210 A (RAJBHANDARI NIRMALA ; UNIV NORTH CAROLINA (US); STOMP ANNE MARIE (U) 18 February 1999 (1999-02-18)	1-5, 8-11, 14-24, 26-28 29,31
Y	page 4 -page 15; claims 1,12-14,21,29-31,38,46-59; example 48	
X	WO 99 19497 A (PERL AVIHAI ; EDELMAN MEIR (IL); FLAISHMAN MOSHE (IL); YEDA RES & D) 22 April 1999 (1999-04-22) page 4; claims 1-10; examples 12-15 page 9 ----- -/--	1,2,8, 14-18, 23,26-28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

8 October 2002

Date of mailing of the international search report

15/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23400

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MURRAY E E ET AL: "CODON USAGE IN PLANT GENES" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 2, 25 January 1989 (1989-01-25), pages 477-498, XP000008653 ISSN: 0305-1048 the whole document	29, 31
Y	WO 99 47678 A (NORDSTROM JEFF ;RALSTON ROBERT (US); ROLLAND ALLAIN (US); GENEMEDI) 23 September 1999 (1999-09-23)	29
A	the whole document	19-22
Y	EP 0 141 484 A (BIOGEN NV) 15 May 1985 (1985-05-15) the whole document	29
Y	WO 98 36085 A (APPLIED PHYTOLOGICS INC ;RODRIGUEZ RAYMOND L (US); SUTLIFF THOMAS) 20 August 1998 (1998-08-20)	31
A	the whole document	3, 24, 25, 32-34
A	WO 94 21796 A (PIONEER HI BRED INT ;US AGRICULTURE (US)) 29 September 1994 (1994-09-29) the whole document	3, 7, 13, 34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/23400

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9907210	A	18-02-1999	AU 8779998 A CN 1272762 T EP 1037523 A1 JP 2001513325 T WO 9907210 A1	01-03-1999 08-11-2000 27-09-2000 04-09-2001 18-02-1999
WO 9919497	A	22-04-1999	WO 9919497 A1 AU 4570397 A AU 9457298 A CA 2312008 A1 EP 1021552 A1 WO 9919498 A1	22-04-1999 03-05-1999 03-05-1999 22-04-1999 26-07-2000 22-04-1999
WO 9947678	A	23-09-1999	AU 3000399 A CA 2323604 A1 EP 1064383 A2 JP 2002506647 T WO 9947678 A2	11-10-1999 23-09-1999 03-01-2001 05-03-2002 23-09-1999
EP 0141484	A	15-05-1985	EP 0141484 A2 JP 60070083 A	15-05-1985 20-04-1985
WO 9836085	A	20-08-1998	AU 746826 B2 AU 6171698 A EP 0981635 A1 JP 2001512318 T WO 9836085 A1 US 6127145 A US 6066781 A	02-05-2002 08-09-1998 01-03-2000 21-08-2001 20-08-1998 03-10-2000 23-05-2000
WO 9421796	A	29-09-1994	US 5569828 A AU 6521494 A WO 9421796 A2	29-10-1996 11-10-1994 29-09-1994

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MURRAY E E ET AL: "CODON USAGE IN PLANT GENES" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 2, 25 January 1989 (1989-01-25), pages 477-498, XP000008653 ISSN: 0305-1048 the whole document	29, 31
Y	WO 99 47678 A (NORDSTROM JEFF ;RALSTON ROBERT (US); ROLLAND ALLAIN (US); GENEMEDI) 23 September 1999 (1999-09-23) the whole document	29
A		19-22
Y	EP 0 141 484 A (BIOGEN NV) 15 May 1985 (1985-05-15) the whole document	29
Y	WO 98 36085 A (APPLIED PHYTOLOGICS INC ;RODRIGUEZ RAYMOND L (US); SUTLIFF THOMAS) 20 August 1998 (1998-08-20) the whole document	31
A		3, 24, 25, 32-34
A	WO 94 21796 A (PIONEER HI BRED INT ;US AGRICULTURE (US)) 29 September 1994 (1994-09-29) the whole document	3, 7, 13, 34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/23400

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9907210	A	18-02-1999	AU 8779998 A CN 1272762 T EP 1037523 A1 JP 2001513325 T WO 9907210 A1	01-03-1999 08-11-2000 27-09-2000 04-09-2001 18-02-1999
WO 9919497	A	22-04-1999	WO 9919497 A1 AU 4570397 A AU 9457298 A CA 2312008 A1 EP 1021552 A1 WO 9919498 A1	22-04-1999 03-05-1999 03-05-1999 22-04-1999 26-07-2000 22-04-1999
WO 9947678	A	23-09-1999	AU 3000399 A CA 2323604 A1 EP 1064383 A2 JP 2002506647 T WO 9947678 A2	11-10-1999 23-09-1999 03-01-2001 05-03-2002 23-09-1999
EP 0141484	A	15-05-1985	EP 0141484 A2 JP 60070083 A	15-05-1985 20-04-1985
WO 9836085	A	20-08-1998	AU 746826 B2 AU 6171698 A EP 0981635 A1 JP 2001512318 T WO 9836085 A1 US 6127145 A US 6066781 A	02-05-2002 08-09-1998 01-03-2000 21-08-2001 20-08-1998 03-10-2000 23-05-2000
WO 9421796	A	29-09-1994	US 5569828 A AU 6521494 A WO 9421796 A2	29-10-1996 11-10-1994 29-09-1994

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/010414 A3(51) International Patent Classification⁷: C12N 15/82,
15/67, 15/62, C07K 14/56Buckden Place, Cary, NC 27511 (US). GASKASKA,
John [US/US]; 102 Lisa Drive, Carrboro, NC 27510 (US).

(21) International Application Number: PCT/US01/23400

(74) Agents: COULTER, Kathryn, L. et al.; Alston & Bird
LLP, Bank of America Plaza, Suite 4000, 101 South Tryon
Street, Charlotte, NC 28280-4000 (US).

(22) International Filing Date: 26 July 2001 (26.07.2001)

(25) Filing Language: English


(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(26) Publication Language: English

(30) Priority Data:
60/221,705 31 July 2000 (31.07.2000) US
60/293,330 23 May 2001 (23.05.2001) US(71) Applicant (for all designated States except US): BIOLEX,
INC. [US/US]; 158 Credle Street, Pittsboro, NC 27312
(US).(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).(72) Inventors; and
(75) Inventors/Applicants (for US only): STOMP,
Anne-Marie [US/US]; 565 East River Road, Mon-
cure, NC 27559 (US). DICKEY, Lynn [US/US]; 111

[Continued on next page]

(54) Title: EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES IN DUCKWEED



(57) Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.

WO 02/010414 A3



Published:

— *with international search report*

(88) Date of publication of the international search report:

27 December 2002

(48) Date of publication of this corrected version:

30 October 2003

(15) Information about Correction:

see PCT Gazette No. 44/2003 of 30 October 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
IN DUCKWEED

FIELD OF THE INVENTION

The present invention relates to methods and compositions for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed.

5 BACKGROUND OF THE INVENTION

The duckweeds are the sole members of the monocotyledonous family Lemnaceae. The four genera and 34 species are all small, free-floating, fresh-water plants whose geographical range spans the entire globe (Landolt (1986)
10 *Biosystematic Investigation on the Family of Duckweeds: The Family of Lemnaceae—A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich). Although the most morphologically reduced plants known, most duckweed species have all the tissues and organs of much larger plants, including roots, stems, flowers, seeds and fronds. Duckweed species have been studied extensively and a substantial literature
15 exists detailing their ecology, systematics, life-cycle, metabolism, disease and pest susceptibility, their reproductive biology, genetic structure, and cell biology. (Hillman (1961) *Bot. Review* 27: 221; Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The Family of Lemnaceae—A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich).

20 The growth habit of the duckweeds is ideal for microbial culturing methods. The plant rapidly proliferates through vegetative budding of new fronds, in a macroscopic manner analogous to asexual propagation in yeast. This proliferation occurs by vegetative budding from meristematic cells. The meristematic region is small and is found on the ventral surface of the frond. Meristematic cells lie in two
25 pockets, one on each side of the frond midvein. The small midvein region is also the site from which the root originates and the stem arises that connects each frond to its mother frond. The meristematic pocket is protected by a tissue flap. Fronds bud

alternately from these pockets. Doubling times vary by species and are as short as 20-24 hours (Landolt (1957) *Ber. Schweiz. Bot. Ges.* 67: 271; Chang *et al.* (1977) *Bull. Inst. Chem. Acad. Sin.* 24:19; Datko and Mudd (1970) *Plant Physiol.* 65:16; Venkataraman *et al.* (1970) *Z. Pflanzenphysiol.* 62: 316).

- 5 Intensive culture of duckweed results in the highest rates of biomass accumulation per unit time (Landolt and Kandeler (1987) *The Family of Lemnaceae—A Monographic Study Vol. 2: Phytochemistry, Physiology, Application, Bibliography, Veröffentlichungen des Geobotanischen Institutes ETH, Stiftung Rubel, Zurich*), with dry weight accumulation ranging from 6-15% of fresh weight (Tillberg *et al.* (1979) *Physiol. Plant.* 46:5; Landolt (1957) *Ber. Schweiz. Bot. Ges.* 67:271; Stomp, unpublished data). Protein content of a number of duckweed species grown under varying conditions has been reported to range from 15-45% dry weight (Chang *et al.* (1977) *Bull. Inst. Chem. Acad. Sin.* 24:19; Chang and Chui (1978) *Z. Pflanzenphysiol.* 89:91; Porath *et al.* (1979) *Aquatic Botany* 7:272; Appenroth *et al.* (1982) *Biochem. Physiol. Pflanz.* 177:251). Using these values, the level of protein production per liter of medium in duckweed is on the same order of magnitude as yeast gene expression systems.
- 10
- 15

- Sexual reproduction in duckweed is controlled by medium components and culturing conditions, including photoperiod and culture density. Flower induction is a routine laboratory procedure with some species. Plants normally self-pollinate, and selfing can be accomplished in the laboratory by gently shaking cultures. By this method, inbred lines of *Lemna gibba* have been developed. Spontaneous mutations have been identified (Slovin and Cohen (1988) *Plant Physiol.* 86, 522), and chemical and gamma ray mutagenesis (using EMS or NMU) have been used to produce mutants with defined characteristics. Outcrossing of *L. gibba* is tedious but can be done by controlled, hand pollination. The genome size of the duckweeds varies from 0.25-1.63 pg DNA/2C with chromosome counts ranging from 20 to 80 and averaging about 40 across the Lemnaceae (Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The family of Lemnaceae—A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich). Ploidy levels are estimated to range from 2-12 C. Id. Genetic diversity within the Lemnaceae has been investigated using secondary products, isozymes, and DNA sequences (McClure and Alston
- 20
- 25
- 30

(1966) *Nature* 4916:311; McClure and Alston (1966) *Amer. J. Bot.* 53:849; Vasseur *et al.* (1991) *Pl. Syst. Evol.* 177:139 (1991); Crawford and Landolt (1993) *Syst. Bot.* 10:389).

Duckweed plant or duckweed nodule cultures can be efficiently transformed with an expression cassette containing a nucleotide sequence of interest by any one of a number of methods including *Agrobacterium*-mediated gene transfer, ballistic bombardment, or electroporation. Stable duckweed transformants can be isolated by transforming the duckweed cells with both the nucleotide sequence of interest and a gene which confers resistance to a selection agent, followed by culturing the transformed cells in a medium containing the selection agent. See U.S. Patent No. 6,040,498 to Stomp *et al.*

A duckweed gene expression system provides the pivotal technology that would be useful for a number of research and commercial applications. For plant molecular biology research as a whole, a differentiated plant system that can be manipulated with the laboratory convenience of yeast provides a very fast system in which to analyze the developmental and physiological roles of isolated genes. For commercial production of valuable polypeptides, a duckweed-based system has a number of advantages over existing microbial or cell culture systems. Plants demonstrate post-translational processing that is similar to mammalian cells, overcoming one major problem associated with the microbial cell production of biologically active mammalian polypeptides, and it has been shown by others (Hiatt (1990) *Nature* 334:469) that plant systems have the ability to assemble multi-subunit proteins, an ability often lacking in microbial systems. Scale-up of duckweed biomass to levels necessary for commercial production of recombinant proteins is faster and more cost efficient than similar scale-up of mammalian cells, and unlike other suggested plant production systems, e.g., soybeans and tobacco, duckweed can be grown in fully contained and controlled biomass production vessels, making the system's integration into existing protein production industrial infrastructure far easier.

These characteristics make duckweed an ideal choice to develop as an efficient, plant-based system for the production of recombinant proteins. Accordingly, the present invention provides methods and compositions that increase

the efficiency of the duckweed gene expression system as a tool for producing biologically active polypeptides.

SUMMARY OF THE INVENTION

5

The present invention is drawn to methods and compositions for the expression and recovery of biologically active recombinant polypeptides, using duckweed as the expression system. One aspect of the present invention provides a method for enhanced expression levels of biologically active polypeptides in
10 duckweed, resulting in an increased polypeptide yield and enabling the production of useful quantities of valuable biologically active polypeptides in this system. Another aspect of the invention discloses methods for the directed secretion of biologically active polypeptides from genetically engineered duckweed plant or duckweed nodule cultures. Secretion of the expressed polypeptide facilitates its recovery and prevents
15 the loss of activity that might result from the mechanical grinding or enzymatic lysing of the duckweed tissue.

In one embodiment, the invention encompasses a method of producing a biologically active recombinant polypeptide in a duckweed plant culture or a duckweed nodule culture, comprising the steps of: (a) culturing within a duckweed
20 culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the polypeptide and an operably linked coding
25 sequence for a signal peptide that directs secretion of the polypeptide into the culture medium; and (b) collecting said biologically active polypeptide from the duckweed culture medium. In some embodiments of this method, the nucleotide sequence has at least one attribute selected from the group consisting of: (a) duckweed-preferred codons in the coding sequence for said polypeptide; (b) duckweed-preferred codons
30 in the coding sequence for said signal peptide; (c) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and (d) an operably linked nucleotide sequence comprising a plant intron that is inserted

upstream of the coding sequence. In some embodiments of this method, the biologically active recombinant polypeptide is secreted into the duckweed culture medium.

In another embodiment, the invention encompasses a method of secreting a biologically active recombinant polypeptide in a duckweed plant culture or a duckweed nodule culture, comprising the steps of: (a) culturing within a duckweed culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the polypeptide into the culture medium; and (b) collecting said biologically active polypeptide from the duckweed culture medium. In some embodiments of this method, the nucleotide sequence has at least one attribute selected from the group consisting of: (a) duckweed-preferred codons in the coding sequence for said polypeptide; (b) duckweed-preferred codons in the coding sequence for said signal peptide; (c) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and (d) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence. In some embodiments of this method, the biologically active recombinant polypeptide is secreted into the duckweed culture medium.

In some embodiments of the above methods, the signal peptide is selected from the group consisting of: (a) the human α -2b-interferon signal sequence; (b) the *Arabidopsis thaliana* chitinase signal sequence; (c) the rice α -amylase signal sequence; (d) the modified rice α -amylase sequence; (e) a duckweed signal sequence; and (f) a signal sequence native to the biologically active recombinant polypeptide. In one embodiment of the method, the signal peptide is the rice α -amylase signal peptide whose sequence is set forth in SEQ ID NO:3.

In some embodiments of the above methods, the duckweed-preferred codons are *Lemna*-preferred codons. In further embodiments, the duckweed-preferred codons

are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons. In further embodiments, at least one coding sequence selected from the coding sequence for the biologically active recombinant polypeptide and the coding sequence for the signal peptide comprises between 70-100 % *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons..

In other embodiments, the invention encompasses a method of producing a biologically active recombinant polypeptide, comprising the steps of: (a) culturing a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is encoded by a nucleotide sequence that has been modified for enhanced expression in duckweed, and (b) collecting said biologically active polypeptide from said duckweed plant culture or said duckweed nodule culture. In some embodiments of this method, the nucleotide sequence that has been modified for enhanced expression in duckweed has at least one attribute selected from the group consisting of: (a) duckweed-preferred codons in the coding sequence for said biologically active recombinant polypeptide; (b) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and (c) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence.

In some embodiments of this method, the duckweed-preferred codons are *Lemna*-preferred codons. In further embodiments, the duckweed-preferred codons are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons. In further embodiments, the coding sequence comprises between 70-100 % *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons.

In some embodiments of the above methods, the plant-preferred translation initiation context nucleotide sequence consists of the nucleotide sequence "ACC" or "ACA", wherein said context is positioned immediately adjacent to the 5' end of the translation initiation codon.

In some embodiments of the above methods, the operably linked nucleotide sequence comprising said plant intron is the sequence set forth in SEQ ID NO:1.

In some embodiments of any of the above methods, the duckweed frond culture or duckweed nodule culture expresses and assembles all of the subunits of a biologically active multimeric protein. In further embodiments, the multimeric protein is selected from the group consisting of collagen, hemoglobin, P450 oxidase, and a monoclonal antibody.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is a mammalian polypeptide. In further embodiments, the mammalian polypeptide is a therapeutic polypeptide. In some embodiments, the mammalian polypeptide is selected from the group consisting of: insulin, growth hormone, α -interferon, β -interferon, β -glucocerebrosidase, β -glucuronidase, retinoblastoma protein, p53 protein, angiostatin, leptin, monoclonal antibodies, cytokines, receptors, human vaccines, animal vaccines, plant polypeptides, and serum albumin.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is α -2b-interferon. In further embodiments, the α -2b-interferon is human α -2b-interferon. In further embodiments, the human α -2b-interferon has the amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:5.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is a biologically active variant of α -2b-interferon, wherein said biologically active variant has at least 80% sequence identity with SEQ ID NO:4 or SEQ ID NO:5.

In some embodiments of any of the above methods, the biologically active recombinant polypeptide is an enzyme.

In other embodiments, the invention encompasses the stably transformed duckweed plant culture or duckweed nodule culture of any of the above methods. In further embodiments, the stably transformed duckweed plant culture or duckweed nodule culture is selected from the group consisting of the genus *Spirodela*, genus *Wolffia*, genus *Wolffiella*, and genus *Lemna*. In further embodiments, the stably transformed duckweed plant culture or duckweed nodule culture is selected from the group consisting of *Lemna minor*, *Lemna miniscula*, *Lemna aequinoctialis*, and *Lemna gibba*.

In other embodiments, the invention encompasses a nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) the amino acid sequence set forth in SEQ ID NO:4; (b) the amino acid sequence set forth in SEQ ID NO:5; (c) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:4, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:4; and (d) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:5, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:5; wherein the nucleotide sequence comprises duckweed-preferred codons. In further embodiments, the nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO:2.

In other embodiments, the invention encompasses a nucleic acid molecule comprising a nucleotide sequence encoding a signal peptide selected from the group consisting of: (a) the rice α -amylase signal peptide amino acid sequence set forth in SEQ ID NO:6; and (b) the modified rice-amylase signal peptide amino acid sequence set forth in SEQ ID NO:7; wherein the nucleotide sequence comprises duckweed-preferred codons. In further embodiments, the nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO: 3.

In other embodiments, the invention encompasses a nucleic acid molecule for the expression and secretion of human α -2b-interferon in duckweed comprising the signal peptide-encoding nucleotide sequence given in SEQ ID NO:3, and the mature human α -2b-interferon-encoding nucleotide sequence given in SEQ ID NO:5, wherein the signal peptide-encoding nucleotide sequence and said mature human α -2b-interferon-encoding nucleotide sequence are operably linked. In further embodiments, the nucleic acid molecule additionally comprises the intron-comprising nucleotide sequence given in SEQ ID NO:1, wherein said intron-comprising nucleotide sequence is operably linked to said signal peptide-encoding nucleotide sequence and said mature human α -2b-interferon-encoding nucleotide sequence.

These and other aspects of the present invention are disclosed in more detail in the description of the invention given below.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1

5 Figure 1 show the interferon levels (as determined by a solid phase sandwich immunoassay) in the media and tissue of a transformed duckweed culture, as described Example 1.

Figure 2

10 Figure 2 show the interferon levels (as determined by a solid phase sandwich immunoassay) in the media and tissue of a transformed duckweed cultures, as described in Example 2.

DETAILED DESCRIPTION OF THE INVENTION

15

In the present invention, methods are disclosed for improving the expression and the recovery of biologically active polypeptides from genetically engineered duckweed plants and duckweed nodule cultures. These methods comprise the steps of

(1) culturing a stably transformed duckweed plant or a duckweed nodule
20 culture that expresses at least one biologically active polypeptide, wherein the polypeptide is encoded by a nucleotide sequence that has been modified for enhanced expression in duckweed, and recovering the biologically active polypeptide from the duckweed culture. Modifications to the nucleotide sequence that are encompassed by this invention include, but are not limited to, the use of duckweed-preferred codons
25 for the coding sequence, the use of a plant-preferred translation initiation context nucleotide sequence for the translation initiation codon, and the insertion of a nucleotide sequence comprising a plant intron sequence upstream of the sequence encoding the polypeptide.

30 (2) Culturing a stably transformed duckweed plant or duckweed nodule culture that expresses at least one biologically active polypeptide comprising a signal sequence that directs secretion of the polypeptide into the culture medium, followed

by recovering the biologically active polypeptide from the culture medium. In one embodiment of this method, the nucleotide sequence encoding the biologically active polypeptide is modified for enhanced expression in duckweed. Alternatively, in another embodiment the nucleotide sequence encoding the signal peptide is modified for enhanced expression in duckweed. In one embodiment, the nucleotide sequence encoding both the biologically active polypeptide and the signal peptide are modified for enhanced expression in duckweed.

As another aspect, the present invention encompasses transformed duckweed plants or duckweed nodule cultures producing biologically active polypeptides according to the methods above.

As another aspect, the present invention discloses methods and nucleic acid sequences for producing biologically active human α -2b-interferon in duckweed.

Definitions:

"Polypeptide" refers to any monomeric or multimeric protein or peptide.

"Biologically active polypeptide" refers to a polypeptide that has the capability of performing one or more biological functions or a set of activities normally attributed to the polypeptide in a biological context. Those skilled in the art will appreciate that the term "biologically active" includes polypeptides in which the biological activity is altered as compared with the native protein (e.g., suppressed or enhanced), as long as the protein has sufficient activity to be of interest for use in industrial or chemical processes or as a therapeutic, vaccine, or diagnostics reagent. Biological activity can be determined by any method available in the art. For example, the biological activity of members of the interferon family of proteins can be determined by any of a number of methods including their interaction with interferon-specific antibodies, their ability to increase resistance to viral infection, or their ability to modulate the transcription of interferon-regulated gene targets.

"Nucleotide sequence of interest" as used herein refers to any nucleotide sequence encoding a polypeptide intended for expression in duckweed. For example, nucleotide sequences encoding therapeutic (e.g., for veterinary or medical uses) or immunogenic (e.g., for vaccination) polypeptides can be expressed using transformed duckweed according to the present invention.

The terms "expression" or "production" refer to the biosynthesis of a gene product, including the transcription, translation, and assembly of said gene product.

The term "duckweed" refers to members of the family Lemnaceae. This family currently is divided into four genera and 34 species of duckweed as follows:

5 genus *Lemna* (*L. aequinoctialis*, *L. disperma*, *L. ecuadoriensis*, *L. gibba*, *L. japonica*, *L. minor*, *L. miniscula*, *L. obscura*, *L. perpusilla*, *L. tenera*, *L. trisulca*, *L. turionifera*, *L. valdiviana*); genus *Spirodela* (*S. intermedia*, *S. polyrrhiza*, *S. punctata*); genus *Wolffia* (*Wa. angusta*, *Wa. arrhiza*, *Wa. australina*, *Wa. borealis*, *Wa. brasiliensis*, *Wa. columbiana*, *Wa. elongata*, *Wa. globosa*, *Wa. microscopica*, *Wa. neglecta*) and

10 genus *Wolffiella* (*Wl. caudata*, *Wl. denticulata*, *Wl. gladiata*, *Wl. hyalina*, *Wl. lingulata*, *Wl. repunda*, *Wl. rotunda*, and *Wl. neotropica*). Any other genera or species of Lemnaceae, if they exist, are also aspects of the present invention. *Lemna* species can be classified using the taxonomic scheme described by Landolt (1986) *Biosystematic Investigation on the Family of Duckweeds: The family of Lemnaceae—*

15 *A Monograph Study* Geobotanischen Institut ETH, Stiftung Rubel, Zurich.

The term "duckweed nodule culture" as used herein refers to a culture comprising duckweed cells wherein at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the cells are differentiated cells. A "differentiated cell," as used herein, is a cell with at least one phenotypic characteristic (e.g., a

20 distinctive cell morphology or the expression of a marker nucleic acid or protein) that distinguishes it from undifferentiated cells or from cells found in other tissue types. The differentiated cells of the duckweed nodule culture described herein form a tiled smooth surface of interconnected cells fused at their adjacent cell walls, with nodules that have begun to organize into frond primordium scattered throughout the tissue.

25 The surface of the tissue of the nodule culture has epidermal cells connect to each other via plasmadesmata.

"Duckweed-preferred codons" as used herein refers to codons that have a frequency of codon usage in duckweed of greater than 17%.

"*Lemna*-preferred codons" as used herein refers to codons that have a

30 frequency of codon usage in the genus *Lemna* of greater than 17%.

"*Lemna gibba*-preferred codons" as used herein refers to codons that have a frequency of codon usage in *Lemna gibba* of greater than 17% where the frequency of

codon usage in *Lemna gibba* was obtained from the Codon Usage Database (GenBank Release 113,0; at [http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+\[gbpln\]](http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+[gbpln])).

5 "Translation initiation codon" refers to the codon that initiates the translation of the mRNA transcribed from the nucleotide sequence of interest.

"Translation initiation context nucleotide sequence" as used herein refers to the identity of the three nucleotides directly 5' of the translation initiation codon.

"Secretion" as used herein refers to translocation of a polypeptide across both the plasma membrane and the cell wall of a host plant cell.

10 "Operably linked" as used herein in reference to nucleotide sequences refers to multiple nucleotide sequences that are placed in a functional relationship with each other. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in reading frame.

15 A. Expression Cassettes

According to the present invention, stably transformed duckweed is obtained by transformation with a nucleotide sequence of interest contained within an expression cassette. The expression cassette comprises a transcriptional initiation region linked to the nucleic acid or gene of interest. Such an expression cassette is provided with a plurality of restriction sites for insertion of the gene or genes of interest (e.g., one gene of interest, two genes of interest, etc.) to be under the transcriptional regulation of the regulatory regions. The expression cassette may encode a single gene of interest. In particular embodiments of the invention, the nucleic acid to be transferred contains two or more expression cassettes, each of which encodes at least one gene of interest.

25 The transcriptional initiation region, (e.g., a promoter) may be native or homologous or foreign or heterologous to the host, or could be the natural sequence or a synthetic sequence. By foreign, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is introduced. As used herein a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

Any suitable promoter known in the art can be employed according to the present invention (including bacterial, yeast, fungal, insect, mammalian, and plant promoters). For example, plant promoters, including duckweed promoters, may be used. Exemplary promoters include, but are not limited to, the Cauliflower Mosaic Virus 35S promoter, the opine synthetase promoters (e.g., nos, mas, ocs, etc.), the ubiquitin promoter, the actin promoter, the ribulose biphosphate (RubP) carboxylase small subunit promoter, and the alcohol dehydrogenase promoter. The duckweed RubP carboxylase small subunit promoter is known in the art (Silverthorne *et al.* (1990) *Plant Mol. Biol.* 15:49). Other promoters from viruses that infect plants, preferably duckweed, are also suitable including, but not limited to, promoters isolated from Dasheen mosaic virus, Chlorella virus (e.g., the Chlorella virus adenine methyltransferase promoter; Mitra *et al.* (1994) *Plant Mol. Biol.* 26:85), tomato spotted wilt virus, tobacco rattle virus, tobacco necrosis virus, tobacco ring spot virus, tomato ring spot virus, cucumber mosaic virus, peanut stump virus, alfalfa mosaic virus, sugarcane bacilliform badnavirus and the like.

Finally, promoters can be chosen to give a desired level of regulation. For example, in some instances, it may be advantageous to use a promoter that confers constitutive expression (e.g., the mannopine synthase promoter from *Agrobacterium tumefaciens*). Alternatively, in other situations, it may be advantageous to use promoters that are activated in response to specific environmental stimuli (e.g., heat shock gene promoters, drought-inducible gene promoters, pathogen-inducible gene promoters, wound-inducible gene promoters, and light/dark-inducible gene promoters) or plant growth regulators (e.g., promoters from genes induced by abscissic acid, auxins, cytokinins, and gibberellic acid). As a further alternative, promoters can be chosen that give tissue-specific expression (e.g., root, leaf, and floral-specific promoters).

The overall strength of a given promoter can be influenced by the combination and spatial organization of cis-acting nucleotide sequences such as upstream activating sequences. For example, activating nucleotide sequences derived from the *Agrobacterium tumefaciens* octopine synthase gene can enhance transcription from the *Agrobacterium tumefaciens* mannopine synthase promoter (see U.S. Patent 5,955,646 to Gelvin *et al.*). In the present invention, the expression cassette can

contain activating nucleotide sequences inserted upstream of the promoter sequence to enhance the expression of the nucleotide sequence of interest. In one embodiment, the expression cassette includes three upstream activating sequences derived from the *Agrobacterium tumefaciens* octopine synthase gene operably linked to a promoter
5 derived from an *Agrobacterium tumefaciens* mannopine synthase gene (see U.S. Patent 5,955,646, herein incorporated by reference).

The transcriptional cassette includes in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a nucleotide sequence of interest, and a transcriptional and translational termination region functional in plants. Any
10 suitable termination sequence known in the art may be used in accordance with the present invention. The termination region may be native with the transcriptional initiation region, may be native with the nucleotide sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthetase and nopaline synthetase
15 termination regions. See also Guerineau *et al.* (1991) *Mol. Gen. Genet.* 262:141; Proudfoot (1991) *Cell* 64:671; Sanfacon *et al.* (1991) *Genes Dev.* 5:141; Mogen *et al.* (1990) *Plant Cell* 2:1261; Munroe *et al.* (1990) *Gene* 91:151; Ballas *et al.* (1989) *Nucleic Acids Res.* 17:7891; and Joshi *et al.* (1987) *Nucleic Acids Res.* 15:9627. Additional exemplary termination sequences are the pea RubP carboxylase small
20 subunit termination sequence and the Cauliflower Mosaic Virus 35S termination sequence. Other suitable termination sequences will be apparent to those skilled in the art.

Alternatively, the gene(s) of interest can be provided on any other suitable expression cassette known in the art.

25 The expression cassettes may contain more than one gene or nucleic acid sequence to be transferred and expressed in the transformed plant. Thus, each nucleic acid sequence will be operably linked to 5' and 3' regulatory sequences. Alternatively, multiple expression cassettes may be provided.

Generally, the expression cassette will comprise a selectable marker gene for
30 the selection of transformed cells or tissues. Selectable marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring

resistance to herbicidal compounds. Herbicide resistance genes generally code for a modified target protein insensitive to the herbicide or for an enzyme that degrades or detoxifies the herbicide in the plant before it can act. See DeBlock *et al.* (1987) *EMBO J.* 6:2513; DeBlock *et al.* (1989) *Plant Physiol.* 91:691; Fromm *et al.* (1990) *BioTechnology* 8:833; Gordon-Kamm *et al.* (1990) *Plant Cell* 2:603. For example, resistance to glyphosphate or sulfonylurea herbicides has been obtained using genes coding for the mutant target enzymes, 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) and acetolactate synthase (ALS). Resistance to glufosinate ammonium, boromoxynil, and 2,4-dichlorophenoxyacetate (2,4-D) have been obtained by using bacterial genes encoding phosphinothricin acetyltransferase, a nitrilase, or a 2,4-dichlorophenoxyacetate monooxygenase, which detoxify the respective herbicides.

For purposes of the present invention, selectable marker genes include, but are not limited to, genes encoding neomycin phosphotransferase II (Fraley *et al.* (1986) *CRC Critical Reviews in Plant Science* 4:1); cyanamide hydratase (Maier-Greiner *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:4250); aspartate kinase; dihydrodipicolinate synthase (Perl *et al.* (1993) *BioTechnology* 11:715); bar gene (Toki *et al.* (1992) *Plant Physiol.* 100:1503; Meagher *et al.* (1996) *Crop Sci.* 36:1367); tryptophan decarboxylase (Goddijn *et al.* (1993) *Plant Mol. Biol.* 22:907); neomycin phosphotransferase (NEO; Southern *et al.* (1982) *J. Mol. Appl. Gen.* 1:327); hygromycin phosphotransferase (HPT or HYG; Shimizu *et al.* (1986) *Mol. Cell. Biol.* 6:1074); dihydrofolate reductase (DHFR; Kwok *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:4552); phosphinothricin acetyltransferase (DeBlock *et al.* (1987) *EMBO J.* 6:2513); 2,2-dichloropropionic acid dehalogenase (Buchanan-Wollaston *et al.* (1989) *J. Cell. Biochem.* 13D:330); acetohydroxyacid synthase (U.S. Pat. No. 4,761,373 to Anderson *et al.*; Haughn *et al.* (1988) *Mol. Gen. Genet.* 221:266); 5-enolpyruvylshikimate-phosphate synthase (aroA; Comai *et al.* (1985) *Nature* 317:741); haloarylnitrilase (WO 87/04181 to Stalker *et al.*); acetyl-coenzyme A carboxylase (Parker *et al.* (1990) *Plant Physiol.* 92:1220); dihydropteroate synthase (sulI; Guerineau *et al.* (1990) *Plant Mol. Biol.* 15:127); and 32 kDa photosystem II polypeptide (psbA; Hirschberg *et al.* (1983) *Science* 222:1346 (1983).

Also included are genes encoding resistance to: gentamycin (*e.g.*, aacC1, Wohlleben *et al.* (1989) *Mol. Gen. Genet.* 217:202-208); chloramphenicol (Herrera-

Estrella *et al.* (1983) *EMBO J.* 2:987); methotrexate (Herrera-Estrella *et al.* (1983) *Nature* 303:209; Meijer *et al.* (1991) *Plant Mol. Biol.* 16:807); hygromycin (Waldron *et al.* (1985) *Plant Mol. Biol.* 5:103; Zhijian *et al.* (1995) *Plant Science* 108:219; Meijer *et al.* (1991) *Plant Mol. Bio.* 16:807); streptomycin (Jones *et al.* (1987) *Mol.*
 5 *Gen. Genet.* 210:86); spectinomycin (Bretagne-Sagnard *et al.* (1996) *Transgenic Res.* 5:131); bleomycin (Hille *et al.* (1986) *Plant Mol. Biol.* 7:171); sulfonamide (Guerineau *et al.* (1990) *Plant Mol. Bio.* 15:127); bromoxynil (Stalker *et al.* (1988) *Science* 242:419); 2,4-D (Streber *et al.* (1989) *BioTechnology* 7:811); phosphinothricin (DeBlock *et al.* (1987) *EMBO J.* 6:2513); spectinomycin (Bretagne-
 10 Sagnard and Chupeau, *Transgenic Research* 5:131).

The bar gene confers herbicide resistance to glufosinate-type herbicides, such as phosphinothricin (PPT) or bialaphos, and the like. As noted above, other selectable markers that could be used in the vector constructs include, but are not limited to, the pat gene, also for bialaphos and phosphinothricin resistance, the ALS gene for
 15 imidazolinone resistance, the HPH or HYG gene for hygromycin resistance, the EPSP synthase gene for glyphosate resistance, the Hm1 gene for resistance to the Hc-toxin, and other selective agents used routinely and known to one of ordinary skill in the art. See Yarranton (1992) *Curr. Opin. Biotech.* 3:506; Chistopherson *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:6314; Yao *et al.* (1992) *Cell* 71:63; Reznikoff (1992) *Mol.*
 20 *Microbiol.* 6:2419; Barkley *et al.* (1980) *The Operon* 177-220; Hu *et al.* (1987) *Cell* 48:555; Brown *et al.* (1987) *Cell* 49:603; Figge *et al.* (1988) *Cell* 52:713; Deuschle *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:5400; Fuerst *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:2549; Deuschle *et al.* (1990) *Science* 248:480; Labow *et al.* (1990) *Mol. Cell. Biol.* 10:3343; Zambretti *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3952; Baim
 25 *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:5072; Wyborski *et al.* (1991) *Nuc. Acids Res.* 19:4647; Hillenand-Wissman (1989) *Topics in Mol. And Struc. Biol.* 10:143; Degenkolb *et al.* (1991) *Antimicrob. Agents Chemother.* 35:1591; Kleinschmidt *et al.* (1988) *Biochemistry* 27:1094; Gatz *et al.* (1992) *Plant J.* 2:397; Gossen *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:5547; Oliva *et al.* (1992) *Antimicrob. Agents*
 30 *Chemother.* 36:913; Hlavka *et al.* (1985) *Handbook of Experimental Pharmacology* 78; and Gill *et al.* (1988) *Nature* 334:721. Such disclosures are herein incorporated by reference.

The above list of selectable marker genes are not meant to be limiting. Any selectable marker gene can be used in the present invention.

B. Modification of Nucleotide Sequences for Enhanced Expression in Duckweed

5 The present invention provides for the modification of the expressed nucleotide sequence to enhance its expression in duckweed. One such modification is the synthesis of the nucleotide sequence of interest using duckweed-preferred codons. Methods are available in the art for synthesizing nucleotide sequences with plant-preferred codons. See, e.g., U.S. Patent Nos. 5,380,831 and 5,436,391; Perlak *et al.* 10 (1991) *Proc. Natl. Acad. Sci. USA* 15:3324; Iannacome *et al.* (1997) *Plant Mol. Biol.* 34:485; and Murray *et al.*, (1989) *Nucleic Acids. Res.* 17:477, herein incorporated by reference. The preferred codons may be determined from the codons of highest frequency in the proteins expressed in duckweed. For example, the frequency of codon usage for *Lemna gibba* is found on the web page:
15 [http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+\[gbpln\]](http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=Lemna+gibba+[gbpln]), and the frequency of codon usage for *Lemna minor* is found on the web page [http://www.kazusa.or.jp/codon/cgibin/showcodon.cgi?species=Lemna+minor+\[gbpln\]](http://www.kazusa.or.jp/codon/cgibin/showcodon.cgi?species=Lemna+minor+[gbpln]). It is recognized that genes which have been optimized for expression in duckweed and other monocots can be used in the methods of the
20 invention. See, e.g., EP 0 359 472, EP 0 385 962, WO 91/16432; Perlak *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:3324; Iannacome *et al.* (1997) *Plant Mol. Biol.* 34:485; and Murray *et al.* (1989) *Nuc. Acids Res.* 17:477, and the like, herein incorporated by reference. It is further recognized that all or any part of the gene sequence may be optimized or synthetic. In other words, fully optimized or partially optimized
25 sequences may also be used. For example, 40 %, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the codons may be duckweed-preferred codons. In one embodiment, between 90 and 96 % of the codons are duckweed-preferred codons. The coding sequence of the nucleotide sequence of interest may comprise codons used with a
30 frequency of at least 17% in *Lemna gibba*. In one embodiment, the modified nucleotide sequence is the human α -2B-interferon encoding nucleotide sequence shown in SEQ ID NO:2, which contains 93% duckweed preferred codons.

Other modifications can also be made to the nucleotide sequence of interest to enhance its expression in duckweed. These modifications include, but are not limited to, elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well characterized sequences which may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence may be modified to avoid predicted hairpin secondary mRNA structures.

There are known differences between the optimal translation initiation context nucleotide sequences for translation initiation codons in animals and plants and the composition of these translation initiation context nucleotide sequence can influence the efficiency of translation initiation. See, for example, Lukaszewicz *et al.* (2000) *Plant Science* 154:89-98; and Joshi *et al.* (1997); *Plant Mol. Biol.* 35:993-1001. In the present invention, the translation initiation context nucleotide sequence for the translation initiation codon of the nucleotide sequence of interest may be modified to enhance expression in duckweed. In one embodiment, the nucleotide sequence is modified such that the three nucleotides directly upstream of the translation initiation codon of the nucleotide sequence of interest are "ACC." In a second embodiment, these nucleotides are "ACA."

Expression of a transgene in duckweed can also be enhanced by the use of 5' leader sequences. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include, but are not limited to, picornavirus leaders, e.g., EMCV leader (Encephalomyocarditis 5' noncoding region; Elroy-Stein *et al.* (1989) *Proc. Natl. Acad. Sci USA* 86:6126); potyvirus leaders, e.g., TEV leader (Tobacco Etch Virus; Allison *et al.* (1986) *Virology* 154:9); human immunoglobulin heavy-chain binding protein (BiP; Macajak and Sarnow (1991) *Nature* 353:90); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4; Jobling and Gehrke (1987) *Nature* 325:622); tobacco mosaic virus leader (TMV; Gallie (1989) *Molecular Biology of RNA*, 23:56); potato etch virus leader (Tomashevskaya *et al.* (1993) *J. Gen. Virol.* 74:2717-2724); Fed-1 5' untranslated region (Dickey (1992) *EMBO J.* 11:2311-2317); RbcS 5' untranslated region (Silverthorne *et al.* (1990) *J. Plant. Mol. Biol.* 15:49-58); and maize chlorotic mottle

virus leader (MCMV; Lommel *et al.* (1991) *Virology* 81:382). See also, Della-Cioppa *et al.* (1987) *Plant Physiology* 84:965. Leader sequence comprising plant intron sequence, including intron sequence from the maize dehydrogenase 1 gene, the castor bean catalase gene, or the Arabidopsis tryptophan pathway gene PAT1 has also
5 been shown to increase translational efficient in plants (Callis *et al.* (1987) *Genes Dev.* 1:1183-1200; Mascarenhas *et al.* (1990) *Plant Mol. Biol.* 15:913-920). In one embodiment of the present invention, nucleotide sequence corresponding to nucleotides 1222-1775 of the maize alcohol dehydrogenase 1 gene (GenBank Accession Number X04049), set forth in SEQ ID NO: 1, is inserted upstream of the
10 nucleotide sequence of interest to enhance the efficiency of its translation.

It is recognized that any of the duckweed expression-enhancing nucleotide sequence modifications described above can be used in the present invention, including any single modification or any possible combination of modifications. The phrase "modified for enhanced expression in duckweed" as used herein refers to a
15 nucleotide sequence that contains any one or any combination of these modifications.

C. Signal Peptides

Secreted proteins are usually translated from precursor polypeptides that include a "signal peptide" that interacts with a receptor protein on the membrane of
20 the endoplasmic reticulum (ER) to direct the translocation of the growing polypeptide chain across the membrane and into the endoplasmic reticulum for secretion from the cell. This signal peptide is often cleaved from the precursor polypeptide to produce a "mature" polypeptide lacking the signal peptide. In an embodiment of the present invention, a biologically active polypeptide is expressed in duckweed from a
25 nucleotide sequence that is operably linked with a nucleotide sequence encoding a signal peptide that directs secretion of the polypeptide into the culture medium. Plant signal peptides that target protein translocation to the endoplasmic reticulum (for secretion outside of the cell) are known in the art. See, for example, U.S. Patent No. 6,020,169 to Lee *et al.* In the present invention, any plant signal peptide can be used
30 to in target polypeptide expression to the ER. In some embodiments, the signal peptide is the *Arabidopsis thaliana* basic endochitinase signal peptide (SEQ ID NO:8; amino acids 14-34 of NCBI Protein Accession No. BAA82823), the extensin signal

peptide (Stiefel *et al.* (1990) *Plant Cell* 2:785-793), the rice α -amylase signal peptide (SEQ ID NO:6; amino acids 1-31 of NCBI Protein Accession No. AAA33885), or a modified rice α -amylase signal sequence (SEQ ID NO:7). In another embodiment, the signal peptide corresponds to the signal peptide of a secreted duckweed protein.

5 Alternatively, a mammalian signal peptide can be used to target recombinant polypeptides expressed in genetically engineered duckweed for secretion. It has been demonstrated that plant cells recognize mammalian signal peptides that target the endoplasmic reticulum, and that these signal peptides can direct the secretion of polypeptides not only through the plasma membrane but also through the plant cell
10 wall. See U.S. Patent Nos. 5,202,422 and 5,639,947 to Hiatt *et al.* In one embodiment of the present invention, the mammalian signal peptide that targets polypeptide secretion is the human α -2b-interferon signal peptide (amino acids 1-23 of NCBI Protein Accession No. AAB59402 and SEQ ID NO:4).

15 In one embodiment, the nucleotide sequence encoding the signal peptide is modified for enhanced expression in duckweed, utilizing any modification or combination of modifications disclosed in section B above for the nucleotide sequence of interest. In another embodiment, the signal peptide the rice α -amylase encoded by the modified nucleotide sequence set forth in SEQ ID NO:3, which contains approximately 93% duckweed preferred codons.

20 The secreted biologically active polypeptide can be harvested from the culture medium by any conventional means known in the art and purified by chromatography, electrophoresis, dialysis, solvent-solvent extraction, and the like.

D. Transformed Duckweed Plants and Duckweed Nodule Cultures

25 The stably transformed duckweed utilized in this invention can be obtained by any method known in the art. In one embodiment, the stably transformed duckweed is obtained by one of the gene transfer methods disclosed in U.S. Patent No. 6,040,498 to Stomp *et al.*, herein incorporated by reference. These methods include gene transfer by ballistic bombardment with microprojectiles coated with a nucleic
30 acid comprising the nucleotide sequence of interest, gene transfer by electroporation, and gene transfer mediated by *Agrobacterium* comprising a vector comprising the nucleotide sequence of interest. In one embodiment, the stably transformed

duckweed is obtained via any one of the *Agrobacterium*-mediated methods disclosed in U.S. Patent No. 6,040,498 to Stomp *et al.* The *Agrobacterium* used is *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes*.

It is preferred that the stably transformed duckweed plants utilized in these methods exhibit normal morphology and are fertile by sexual reproduction. Preferably, transformed plants of the present invention contain a single copy of the transferred nucleic acid, and the transferred nucleic acid has no notable rearrangements therein. Also preferred are duckweed plants in which the transferred nucleic acid is present in low copy numbers (i.e., no more than five copies, alternately, no more than three copies, as a further alternative, fewer than three copies of the nucleic acid per transformed cell).

The stably transformed duckweed expresses a biologically active protein hormone, growth factor, or cytokine, insulin, or growth hormone (in particular, human growth hormone). Alternatively, the duckweed expresses biologically active β -glucuronidase. The duckweed may express biologically active α -2b-interferon, for example human α -2b-interferon precursor (NCBI Protein Accession No. AAB59402; set forth in SEQ ID NO:4) or mature human α -2b-interferon (amino acids 24-188 of NCBI Protein Accession No. AAB9402; set forth in SEQ ID NO:5) or biologically active variants thereof.

By "biologically active variant" of human α -2b-interferon is intended a polypeptide derived from the native polypeptide by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Biologically active variant α -2b-interferon polypeptides encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native α -2b-interferon including the ability to increase resistance to viral infection, or the ability to modulate the transcription of α -2b-interferon-regulated gene targets. Such biologically active variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native α -2b-interferon protein of the

invention will have at least about 50%, 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:5. Thus, a biologically active
5 variant of an α -2b-interferon of the invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue. Examples of biologically active variants of human α -interferon are known in the art. See, for example, European patent EP211148B1, and U.S. Patent Nos. 4,748,233, 4,801,685, 4,816,566, 4,973,479, 4,975,276,
10 5,089,400, 5,098,703, 5,231,176, and 5,869,293; herein incorporated by reference.

The comparison of sequences and determination of percent identity and percent similarity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (1970) *J. Mol. Biol.*
15 48:444-453 algorithm, which is incorporated into the GAP program in the GCG software package (available at www.accelrys.com), using either a BLOSSUM62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG
20 software package, using a BLOSUM62 scoring matrix (see Henikoff *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used if the practitioner is uncertain about what parameters should be applied to determine if a molecule is within a sequence identity limitation of the
25 invention) is using a BLOSUM62 scoring matrix with a gap weight of 60 and a length weight of 3).

The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller (1989) *CABIOS* 4:11-17 which has been incorporated into the ALIGN program (version 2.0), using a
30 PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

In one embodiment, the stably transformed duckweed plants or duckweed nodule cultures express biologically active polypeptides that cannot effectively be

commercially produced by existing gene expression systems, because of cost or logistical constraints, or both. For example, some proteins cannot be expressed in mammalian systems because the protein interferes with cell viability, cell proliferation, cellular differentiation, or protein assembly in mammalian cells. Such proteins include, but are not limited to, retinoblastoma protein, p53, angiostatin, and leptin. The present invention can be advantageously employed to produce mammalian regulatory proteins; it is unlikely given the large evolutionary distance between higher plants and mammals that these proteins will interfere with regulatory processes in duckweed. Transgenic duckweed can also be used to produce large quantities of proteins such as serum albumin (in particular, human serum albumin), hemoglobin, and collagen, which challenge the production capabilities of existing expression systems.

Finally, higher plant systems can be engineered to produce biologically active multimeric proteins (e.g., monoclonal antibodies, hemoglobin, P450 oxidase, and collagen, and the like) far more easily than can mammalian systems. One exemplary approach for producing biologically active multimeric proteins in duckweed uses an expression vector containing the genes encoding all of the polypeptide subunits. See, e.g., During *et al.* (1990) *Plant Mol. Biol.* 15:281 and van Engelen *et al.* (1994) *Plant Mol. Biol.* 26:1701. This vector is then introduced into duckweed cells using any known transformation method, such as a ballistic bombardment or *Agrobacterium*-mediated transformation. This method results in clonal cell lines that express all of the polypeptides necessary to assemble the multimeric protein. A variation on this approach is to make single gene constructs, mix DNA from these constructs together, then deliver this mixture of DNAs into plant cells using ballistic bombardment or *Agrobacterium*-mediated transformation. As a further variation, some or all of the vectors may encode more than one subunit of the multimeric protein (i.e., so that there are fewer duckweed clones to be crossed than the number of subunits in the multimeric protein). In an alternative embodiment, each duckweed clone expresses at least one of the subunits of the multimeric protein, and duckweed clones secreting each subunit are cultured together and the multimeric protein is assembled in the media from the various secreted subunits. In some instances, it may be desirable to produce less than all of the subunits of a multimeric protein, or even a single protein

subunit, in a transformed duckweed plant or duckweed nodule culture, e.g., for industrial or chemical processes or for diagnostic, therapeutic, or vaccination purposes.

5

EXPERIMENTAL

The following examples are offered for purposes of illustration, not by way of limitation.

10 Expression Vectors

The expression vector pBMSP-1 used in some of the examples is described in U.S. Patent No. 5,955,646, herein incorporated by reference. The pBMSP-1 transcriptional cassette contains three copies of a transcriptional activating nucleotide sequence derived from the *Agrobacterium tumefaciens* octopine synthase and, an additional transcriptional activating nucleotide sequence derived from the *Agrobacterium tumefaciens* mannopine synthase gene, a promoter region derived from the *Agrobacterium tumefaciens* mannopine synthase gene, a polylinker site for insertion of the nucleotide sequence encoding the polypeptide of interest, and a termination sequence derived from the *Agrobacterium tumefaciens* nopaline synthase gene. The pBMSP-1 expression vector also contains a nucleotide sequence coding for neomycin phosphotransferase II as a selectable marker. Transcription of the selectable marker sequence is driven by a promoter derived from the *Agrobacterium tumefaciens* nopaline synthase gene.

The expression vector pBMSP-3, also used in some of the following examples, contains the components of the pBMSP-1 expression vector described above and additionally contains a nucleotide sequence corresponding to nucleotides 1222-1775 of the maize alcohol dehydrogenase gene (GenBank Accession Number X04049) inserted between the promoter and the polylinker.

Expression Constructs for the Production of Human α -2b-Interferon in Duckweed

The following expression constructs were constructed using methods well known in the art. See, for example, Sambrook, J., Fritsh, E. F., and Maniatis, T.

Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory,

5 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

Table 1

Construct Name	Expression Vector	Signal Peptide	Interferon-encoding Sequence
IFN01	pBMSP-1	None	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN02	pBMSP-3	Non-optimized interferon (nucleotides 511-579 of GenBank Accession No. J00207)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN03	pBMSP-3	<i>Arabidopsis thaliana</i> endochitinase (nucleotides 338-399 of GenBank Accession number AB023460 with an additional "A" added to the 3' end of the sequence)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN05	pBMSP-3	Modified rice α -amylase * (encoding the amino acid sequence shown in SEQ ID NO:7)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN07	pBMSP-3	Wild type rice α -amylase (nucleotides 34-126 of GenBank Accession No. M24286, encoding the amino acid sequence shown in SEQ ID NO:6)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN08	pBMSP-3	Optimized wild type rice α -amylase (SEQ ID NO:3)	Non-optimized interferon (nucleotides 580-1077 of GenBank Accession No. J00207)
IFN09	pBMSP-3	Optimized wild type rice α -amylase (SEQ ID NO:3)	Optimized interferon (SEQ ID NO:2)
IFN10	pBMSP-3	None	Optimized interferon (SEQ ID NO:2)
IFN11	pBMSP-1	Optimized wild type rice α -amylase (SEQ ID NO:3)	Optimized interferon (SEQ ID NO:2)
IFN12	pBMSP-1	None	Optimized interferon (SEQ ID NO:2)

*The nucleotide sequence encoding the modified rice α -amylase signal peptide corresponds to nucleotides 34-126 of GenBank Accession No. M24286, except that nucleotides 97-102 have been changed from "CTTGGC" to "ATCGTC."

5 Transformation of Duckweed

Duckweed fronds or duckweed nodule cultures (derived from *Lemna minor* strain 8627 in these examples) are transformed with the expression constructs described above using Agrobacteria-mediated transformation methods.

- Agrobacterium tumefaciens* strain C58Z707, a disarmed, broad host range C58 strain (Hepburn *et al.* (1985) *J. Gen. Microbiol.* 131:2961-2969) is used for transformation in these examples. The expression constructs described above are mobilized into *A. tumefaciens* by electroporation, or by a triparental mating procedure using *E. coli* MM294 harboring the mobilizing plasmid pRK2013 (Hoekema *et al.* (1983) *Nature* 303: 179-180; Ditta *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77: 7347-7350).
- 15 C58Z707 strains comprising the expression constructs described above are streaked on AB minimal medium (Chilton *et al.*, (1974) *Proc. Nat. Acad. Sci. USA* 71: 3672 - 3676) or in YEB medium (1 g/L yeast extract, 5 g/L beef extract, 5 g/L peptone, 5 g/L sucrose, 0.5 g/L $MgSO_4$) containing streptomycin at 500 mg/L, spectinomycin at 50 mg/L and kanamycin sulfate at 50 mg/L and grown overnight at 28° C.

- 20 In these examples, *Lemna minor* strain 8627 is used for transformation although any *Lemna* strain can be used. Fronds are grown on liquid Schenk and Hildebrandt medium (Schenk and Hildebrandt (1972) *Can. J. Bot.* 50:199) containing 1% sucrose and 10 μ M indoleacetic acid at 23° C. under a 16 hour light/8 hour dark photoperiod with light intensity of approximately 40 μ M/m²·sec. For inoculation,
- 25 individual fronds are separated from clumps and floated in inoculation media for approximately 2 to 20 minutes. The inoculating medium is Schenk and Hildebrandt medium (pH 5.6) supplemented with 0.6 M mannitol and 100 μ M acetosyringone, with the appropriate *Agrobacterium tumefaciens* strain comprising the expression construct present at a concentration of about 1×10^9 cells/ml. These fronds are then
- 30 transferred to Schenk and Hildebrandt medium (pH 5.6) containing 1% sucrose, 0.9%

agar, and 20 mg/L acetosyringone and are co-cultivated for 3 or 4 days in the dark at 23° C.

Following co-cultivation, the fronds are transferred for recovery to Schenk and Hildebrandt medium or Murashige and Skoog medium (Murashige and Skoog (1962) *Physiol. Plant.* 15:473) supplemented with 200 µg/ml kanamycin sulfate. Fronds are decontaminated from infecting *Agrobacteria* by transferring the infected tissue to fresh medium with antibiotic every 2-4 days. The fronds are incubated on this medium for approximately four weeks under conditions of low light (1-5 µM/m²·sec).

Duckweed nodule cultures for transformation are produced as follows.

10 Duckweed fronds are separated, the roots are cut off with a sterile scalpel, and the fronds are placed, ventral side down, on Murashige and Skoog medium (catalog number M-5519; Sigma Chemical Corporation, St. Louis, MO) pH 5.6, supplemented with 5 µM 2,4-dichlorophenoxyacetic acid, 0.5 µM 1-Phenyl-3(1,2,3-thiadiazol-5-yl) urea thidiazuron (Sigma P6186), 3% sucrose, 0.4 Difco Bacto-agar (Fisher Scientific),
15 and 0.15% Gelrite (Sigma). Fronds are grown for 5-6 weeks. At this time, the nodules (small, yellowish cell masses) appear, generally from the central part of the ventral side. This nodule tissue is detached from the mother frond and cultured in Murashige and Skoog medium supplemented with 3% sucrose, 0.4% Difco Bacto-agar, 0.15% Gelrite, 1 µM 2,4-dichlorophenoxyacetic acid, and 2 µM benzyladenine.

20 Duckweed nodule cultures are transformed as follows. The appropriate *Agrobacterium tumefaciens* strain is grown on potato dextrose agar or YEB agar with 50 mg/L kanamycin and 100 µM acetosyringone, and resuspended in Murashige and Skoog medium supplemented with 0.6 M Mannitol and 100 µM acetosyringone. Nodule culture tissue is inoculated by immersing in the solution of resuspended
25 bacteria for 1-2 minutes, blotted to remove excess fluid, and plated on co-cultivation medium consisting of Murashige and Skoog medium supplemented with auxin and cytokinin optimized to promote nodule growth and 100 µM acetosyringone.

For selection, nodule culture tissue is transferred to regeneration medium Murashige and Skoog medium with 3% sucrose, 1 µM 2,4-dichlorophenoxyacetate, 2
30 µM benzyladenine, 0.4 % Difco Bacto-Agar, 0.15% Gelrite 500 mg/L cefotaxime, and 200 mg/L kanamycin sulfate and cultured for approximately four weeks under

continuous light (20-40 $\mu\text{M}/\text{m}^2\cdot\text{sec}$). The nodule tissue is transferred every 7 days to fresh culture medium. Selection is complete when the nodule tissue shows vigorous growth on the selection agent. In some examples, the transformed duckweed nodule cultures are transferred directly to regeneration medium for selection, instead of
5 undergoing selection in co-cultivation medium.

For regeneration of transformed duckweed, the selected nodule culture is transferred to regeneration medium (0.5 X Schenk and Hildebrandt medium supplemented with 1% sucrose and 200 mgs/L kanamycin) to organize and produce plants. The nodule culture is incubated on regeneration medium under full light for
10 approximately 3 weeks, until fronds appear. Fully organized fronds are transferred to liquid Schenk and Hildebrandt medium with 1-3% sucrose and incubated under full light for further clonal proliferation.

Detection of Biologically-Active Interferon Produced from Duckweed Fronds or
15 Duckweed Nodule Culture

Biologically-active interferon is detected by various assays, including a solid phase sandwich immunoassay as described in Staehlin *et al.* (1981) *Methods Enzymol.* 79:589-594 and Kelder *et al.* (1986) *Methods Enzymol.* 119:582-587, herein incorporated by reference, and a cytopathic effect inhibition assay (described in
20 Tovey *et al.* (1978) *Nature* 276:270-272, herein incorporated by reference. Secreted interferon is collected from the duckweed culture medium, while non-secreted interferon is collected from ground-up or lysed duckweed plants or duckweed nodule tissue.

The solid phase sandwich immunoassay for interferon is performed using a kit
25 from PBL Laboratories (New Brunswick, NJ) according to the manufacturer's instructions. Briefly, interferon is captured by an antibody bound to the microtiter plate wells. A second antibody is then used to reveal the bound antibody. An anti-secondary antibody conjugated to horseradish peroxidase (HRP) is then used to mark the interferon. Tetramethyl benzidine (TMB) initiates a peroxidase-catalyzed color
30 change so that the interferon level can be observed and compared with a standard. A monoclonal antibody specific for α -2b-interferon (Cat. No. 11105, PBL Laboratories) is used for this assay in the present examples.

The cytopathic effect inhibition assay is performed according to the methods of Tovey *et al.* (1978) *Nature* 276:270-272. Briefly, serial two-fold dilutions of the preparation to be assayed are diluted in a 96 well microtiter plate (Falcon Inc) in a volume of 100 μ l of Eagles minimal essential medium (Life Technologies Inc) supplemented with 2 % fetal calf serum (Life Technologies Inc) in parallel with serial two fold dilutions of the US National Institutes of Health human IFN alpha international reference preparation (G-002-901-527). Twenty thousand human amnion cells (line WISH) are then added to each well of the microtiter plate in a volume of 100 μ l of medium with 2 % fetal calf serum. The cells are incubated over-night in an atmosphere of 5 % CO₂ in air at 37°C, the medium is removed and replaced with 200 μ l of medium with 2 % fetal calf serum containing vesicular stomatitis virus at a multiplicity of infection of 0.1. The cells are further incubated over-night in an atmosphere of 5 % CO₂ in air at 37 °C and the cytopathic effect due to virus replication is then evaluated under a light microscope. Interferons titers are expressed as the reciprocal of the IFN dilution which gave 50 % protection against the cytopathic effects of the virus. Interferon titers are expressed in international reference units by reference to the titer of the reference preparation.

The following examples demonstrate the expression of biologically active interferon in duckweed.

Example 1

A study was performed to determine culture IFN levels in media and tissue at various time points in a batch culture. A set of 20-30ml 175oz.-culture jars were inoculated on Day 0 with 20 fronds of a line previously identified as expressing detectable levels of human α -2b-interferon (IFN). The cultures were grown under autotrophic, buffered conditions with continuous high light provided by plant/aquarium fluorescent grow bulbs. At each time point - days 5, 7, 13, 15, and 18 – the fresh weight and media volume were measured for four cultures. From each culture, media and tissue samples were obtained and a plant protease inhibitor cocktail was added. The tissue samples were ground and spun cold. The supernatant was collected. Media and tissue extracts were stored at -70°C until all samples were collected. IFN levels in media and tissue extracts were determined on the same day

using the solid phase sandwich immunoassay described above. Total culture IFN in media and tissue was calculated by multiplying measured IFN concentrations and the volume of media and the fresh weight for the culture, respectively. Figure 1 shows the relative IFN levels on days 7, 13, 15, and 18 compared to day 5. The last time point represents the average value for three cultures instead of four due to loss of one culture.

Example 2

A study was performed to determine culture IFN levels in media and tissue at various time points in a batch culture. A set of 24-30ml 175oz.-culture jars were inoculated on Day 0 with 20 fronds same line as in Example 1. The cultures were grown under autotrophic, unbuffered conditions with continuous high light provided by plant/aquarium fluorescent grow bulbs. At each time point - days 7, 10, 12, 14, 17, and 19 - the fresh weight and media volume were measured for four cultures. From each culture, media and tissue samples were obtained and a plant protease inhibitor cocktail was added. The tissue samples were ground and spun cold. The supernatant was collected. Media and tissue extracts were stored at -70°C until all samples were collected. IFN levels in media and tissue extracts were determined on the same day using the solid phase sandwich immunoassay described above. Total culture IFN in media and tissue was calculated by multiplying measured IFN concentrations and the volume of media and the fresh weight for the culture, respectively. Figure 2 shows the relative IFN levels on days 14, 17, and 19 compared to day 12. Media IFN levels on day 7 and day 10 were below the range of the extended range protocol for the immunoassay.

Example 3

Duckweed lines transformed with the expression constructs listed in Table 1 were produced using the methods described above. These transformed duckweed lines were grown for 14 days under autotrophic conditions. Bovine serum albumin at a concentration of 0.2 mg/ml was included in the growth media. On day 14, media and tissue extracts were prepared as described in Example 1, and the interferon levels in these extracts were determined using the solid phase sandwich immunoassay as

described above. Table 2 gives the number of clonal duckweed lines assayed and the mean media interferon concentration for each expression construct. Table 3 shows the interferon levels within the duckweed tissue for the duckweed lines transformed with the interferon expression constructs that did not contain a signal peptide (IFN01, IFN10, and IFN12). Both the mean interferon level for all clonal lines assayed for the designated construct, and the interferon level for the top-expressing line are shown.

Table 2

Expression Construct	# of Clonal Lines	Mean Interferon
	<u>Tested</u>	<u>Concentration</u> (ng/ml)
IFN01	41	0
IFN02	75	2.3
IFN03	41	0.18
IFN05	44	2.5
IFN07	41	1.5
IFN08	41	1.4
IFN09	41	30.3
IFN10	41	0
IFN11	39	9.9
IFN12	41	0

10

Table 3

IFN Construct	Mean Value	Top Expresser
	% of total soluble protein	% of total soluble protein
IFN01	0.00003	0.0001
IFN10	0.00064	0.0074
IFN12	0.00014	0.001

15

The biological activity of the interferon produced by these transformed duckweed lines was assayed by the cytopathic effect inhibition assay described above. Table 4 gives the results for the top expressing line for each construct. The interferon

activity is shown for the media for those constructs containing a signal peptide and the tissue for those constructs lacking a signal peptide.

Table 4

IFN Construct	Top Expresser	
	Source material	IU/ml (media) IU/mg total protein (tissue)
IFN01	Tissue	40
IFN02	Media	16,000
IFN03	Media	320
IFN05	Media	6,400
IFN07	Media	6,000
IFN08	Media	3,200
IFN09	Media	200,000
IFN10	Tissue	19,300
IFN11	Media	30,000
IFN12	Tissue	150

5

The following features can be noted for the data in this example: (1) Secretion of interferon was detected only for those duckweed lines transformed with expression constructs containing a signal peptide. Compare, for example, the media interferon concentration for IFN02, IFN03, IFN05, IFN07, IFN08, IFN 09 and IFN011 with that for IFN01, IFN10, and IFN12. (2) Secretion of interferon was detected for all expression constructs containing a signal peptide, with the native human interferon signal sequence producing the highest level of secreted interferon. Compare, for example, the interferon levels produced by IFN02 with those produced by IFN03 and IFN05. (3) The use of duckweed-preferred codons leads to enhanced interferon expression. Compare, for example, the interferon levels produced by IFN09 with those for IFN05. (4) Higher expression levels were achieved by the codon optimization of more than just the signal peptide. Compare, for example, IFN08 with IFN09. (5) Including the maize alcohol dehydrogenase intron sequence in the expression construct resulted in higher levels of interferon expression. Compare, for example, IFN09 with IFN11 and IFN10 with IFN12. (6) No statistically significant difference was observed between the interferon levels expressed from the construct

20

containing the modified α -amylase signal peptide (IFN05) in comparison with that containing the wild-type alpha amylase signal peptide (IFN07).

5 All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains: All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method of producing a biologically active recombinant polypeptide in a duckweed plant culture or a duckweed nodule culture, comprising the steps of:
- 5 (a) culturing within a duckweed culture medium a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and wherein said biologically active recombinant polypeptide is expressed from a nucleotide sequence comprising a coding sequence
- 10 for the polypeptide and an operably linked coding sequence for a signal peptide that directs secretion of the polypeptide into the culture medium; and
- (b) collecting said biologically active polypeptide from the duckweed culture medium.
- 15 2. The method of claim 1, wherein said biologically active recombinant polypeptide is secreted into the duckweed culture medium.
3. The method of claim 1, wherein said nucleotide sequence has at least one attribute selected from the group consisting of:
- 20 (a) duckweed-preferred codons in the coding sequence for said polypeptide;
- (b) duckweed-preferred codons in the coding sequence for said signal peptide;
- (c) a translation initiation codon that is flanked by a plant-preferred
- 25 translation initiation context nucleotide sequence; and
- (d) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence.
4. The method according to claim 3, wherein said duckweed-preferred
- 30 codons are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons..

5. The method according to claim 4, wherein at least one coding sequence selected from the coding sequence for said polypeptide and the coding sequence for said signal peptide comprises between 70-100 % *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons..
- 5
6. The method according to claim 3, wherein said plant-preferred translation initiation context nucleotide sequence consists of the nucleotide sequence "ACC" or "ACA", wherein said context is positioned immediately adjacent to of the 5' end of the translation initiation codon.
- 10
7. The method according to claim 3, wherein said operably linked nucleotide sequence comprising said plant intron is the sequence set forth in SEQ ID NO:1.
- 15
8. A method of producing a biologically active recombinant polypeptide, comprising the steps of:
- (a) culturing a duckweed plant culture or a duckweed nodule culture, wherein said duckweed plant culture or said duckweed nodule culture is stably transformed to express said biologically active recombinant polypeptide, and
- 20 wherein said biologically active recombinant polypeptide is encoded by a nucleotide sequence that has been modified for enhanced expression in duckweed, and
- (b) collecting said biologically active polypeptide from said duckweed plant culture or said duckweed nodule culture.
- 25
9. The method of claim 8, wherein said nucleotide sequence that has been modified for enhanced expression in duckweed has at least one attribute selected from the group consisting of:
- (a) duckweed-preferred codons in the coding sequence for said biologically active recombinant polypeptide;
- 30 (b) a translation initiation codon that is flanked by a plant-preferred translation initiation context nucleotide sequence; and

(c) an operably linked nucleotide sequence comprising a plant intron that is inserted upstream of the coding sequence.

10. The method according to claim 9, wherein said duckweed-preferred
5 codons are *Lemna gibba*-preferred codons or *Lemna minor*-preferred codons.

11. The method according to claim 10, wherein the coding sequence
comprises between 70% and 100% *Lemna gibba*-preferred codons or *Lemna minor*-
preferred codons.

10

12. The method according to claim 9, wherein said plant-preferred
translation initiation context nucleotide sequence consists of the nucleotide sequence
"ACC" or "ACA", wherein said context is positioned immediately adjacent to the 5'
end of the translation initiation codon.

15

13. The method according to claim 9, wherein said operably linked
nucleotide sequence comprising said plant intron is the sequence set forth in SEQ ID
NO:1.

20

14. The method according to claim 1, wherein said duckweed frond culture
or duckweed nodule culture expresses and assembles all of the subunits of a
biologically active multimeric protein.

15. The method according to claim 14, wherein said biologically active
25 multimeric protein is selected from the group consisting of collagen, hemoglobin,
P450 oxidase, and a monoclonal antibody.

16. The method according to claim 1, wherein the biologically active
recombinant polypeptide is a mammalian polypeptide.

30

17. The method according to claim 16, wherein the mammalian
polypeptide is a therapeutic polypeptide.

18. The method according to claim 16, wherein the mammalian polypeptide is selected from the group consisting of insulin, growth hormone, α -interferon, β -interferon, β -glucocerebrosidase, β -glucuronidase, retinoblastoma protein, p53 protein, angiostatin, leptin, monoclonal antibodies, cytokines, receptors,
5 human vaccines, animal vaccines, plant polypeptides, and serum albumin.

19. The method according to claim 1, wherein the biologically active recombinant polypeptide is α -2b-interferon.

10

20. The method according to claim 19, wherein said α -2b-interferon is human α -2b-interferon.

21. The method according to claim 20, wherein said human α -2b-interferon has the amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:5.
15

22. The method according to claim 1, wherein the biologically active recombinant polypeptide is a biologically active variant of α -2b-interferon, wherein said biologically active variant has at least 80% sequence identity with SEQ ID NO:4
20 or SEQ ID NO:5.

23. The method according to claim 1, wherein the biologically active recombinant polypeptide is an enzyme.

24. The method according to claim 1, wherein said signal peptide sequence is selected from the group consisting of:
25

- (a) the human α -2b-interferon signal peptide;
 - (b) the *Arabidopsis thaliana* chitinase signal peptide;
 - (c) the rice α -amylase signal peptide;
 - (d) the modified rice α -amylase peptide;
 - (e) a duckweed signal peptide; and
- 30

(f) a signal peptide native to the biologically active recombinant polypeptide.

25. The method according to claim 24, wherein the signal peptide is the rice α -amylase signal peptide having the sequence set forth in SEQ ID NO:3.

26. The stably transformed duckweed plant culture or duckweed nodule culture according to claim 1.

27. The stably transformed duckweed plant culture or duckweed nodule culture according to claim 26, wherein said duckweed plant culture or duckweed nodule culture is selected from the group consisting of the genus *Spirodela*, genus *Wolffia*, genus *Wolffiella*, and genus *Lemna*.

28. The stably transformed duckweed plant culture or duckweed nodule culture according to claim 27, wherein said duckweed plant culture or duckweed nodule culture is selected from the group consisting of *Lemna minor*, *Lemna miniscula*, *Lemna aequinoctialis*, and *Lemna gibba*.

29. A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence set forth in SEQ ID NO:4;
(b) the amino acid sequence set forth in SEQ ID NO:5;
(c) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:4, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:4; and

(d) the amino acid sequence of a biologically active variant of the amino acid sequence shown in SEQ ID NO:5, wherein said biologically active variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO:5;

wherein said nucleotide sequence comprises duckweed-preferred codons.

30. The nucleic acid molecule of claim 29, wherein said nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO: 2.

5 31. A nucleic acid molecule comprising a nucleotide sequence encoding a signal peptide selected from the group consisting of:

(a) the rice α -amylase signal peptide amino acid sequence set forth in SEQ ID NO:6; and

(b) the modified rice-amylase signal peptide amino acid sequence
10 set forth in SEQ ID NO:7;
wherein said nucleotide sequence comprises duckweed-preferred codons.

32. The nucleic acid molecule of claim 31, wherein said nucleotide sequence is the nucleotide sequence set forth in SEQ ID NO: 3.


15

33. A nucleic acid molecule of claim 29, wherein said nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:5 and further comprises the signal peptide-encoding nucleotide sequence given in SEQ ID NO:3, and said nucleotide sequence set forth in SEQ ID NO:5 and said signal peptide-
20 encoding nucleotide sequence given in SEQ ID NO:3 are operably linked.

34. The nucleic acid molecule of claim 33, additionally comprising the intron-comprising nucleotide sequence given in SEQ ID NO:1, wherein said intron-comprising nucleotide sequence, said signal peptide-encoding nucleotide sequence
25 and said mature human α -2b-interferon-encoding nucleotide sequence are operably linked.

1/2


EXAMPLE 1: RELATIVE IFN LEVELS IN TISSUE AND MEDIA



SUBSTITUTE SHEET (RULE 26)

2/2

EXAMPLE 2: RELATIVE IFN LEVELS IN MEDIA AND TISSUE



SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> Biolex, Inc.
 Stomp, Anne-Marie
 Dickey, Lynn
 Gasdaska, John

<120> Expression of Biologically Active
 Polypeptides in Duckweed

<130> 40989/237187

<150> US 60/293,330

<151> 2001-05-23

<150> US 60/221,705

<151> 2000-07-31

<160> 8

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 554

<212> DNA

<213> Zea mays

<400> 1

```

gatcaagtgc aaaggtccgc cttgtttctc ctctgtctct tgatctgact aatcttggtt 60
tatgattcgt tgagtaattt tggggaaagc ttctgtccaca gttttttttt cgatgaacag 120
tgccgcagtg gcgctgatct tgtatgctat cctgcaatcg tgggtgaactt atgtctttta 180
tattccttcac taccatgaaa agactagtaa tctttctcga tgtaacatcg tccagcactg 240
ctattaccgt gtggtccatc cgacagtcctg gctgaacaca tcatacgata ttgagcaaag 300
atctatcttc cctgttcttt aatgaaagac gtcattttca tcagtatgat ctaagaatgt 360
tgcaacttgc aaggaggcgt ttctttcttt gaatttaact aactcgttga gtggccctgt 420
ttctcggaag taaggccttt gctgtccac acatgtccat tcgaatttta ccgtgttttag 480
caagggcgaa aagtttgcatt cttgatgatt tagcttgact atgcgattgc tttcctggac 540
ccgtgcagct gcgg                                     554
  
```

<210> 2

<211> 498

<212> DNA

<213> Artificial Sequence

<220>

<223> Duckweed codon optimized nucleotide sequence
 encoding human alpha-2B interferon

<221> CDS

<222> (1)...(498)

<400> 2

```

tgc gac ctc ccc cag acc cac agc ctc ggg tcc cgc cgc acc ctc atg 48
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
1 5 10 15

ctg ctg gcg cag atg cgc cgc atc tcg ctc ttc agc tgc ctg aag gac 96
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30

cgc cac gac ttc ggc ttc ccg cag gag gag ttc ggc aac cag ttc cag 144
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
35 40 45
  
```

```

aag gcc gag acg atc ccc gtg ctc cac gag atg atc cag cag atc ttc 192
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
    50                55                60

aac ctg ttc agc acc aag gac agc tcg gcc gcc tgg gac gag acc ctg 240
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
    65                70                75                80

ctc gac aag ttc tac acc gag ctg tac cag cag ctc aac gac ctg gag 288
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
                85                90                95

gcg tgc gtg atc cag ggg gtt ggg gtt acg gag acg ccg ctg atg aag 336
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                100                105                110

gag gac agc atc ctc gcc gtg cgc aag tac ttc cag cgc atc acg ctc 384
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                115                120                125

tac ctc aag gag aag aag tac agc ccg tgc gcc tgg gag gtc gtt cgc 432
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
                130                135                140

gcc gag atc atg cgc tcc ttc agc ctg agc acc aac ctc cag gag agc 480
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
                145                150                155                160

ctc cgc tcc aag gag taa 498
Leu Arg Ser Lys Glu *
                165

```

<210> 3
 <211> 96
 <212> DNA
 <213> Oryza sativa

<400> 3
 accatgcagg tccatgaacac gatgggtcaac aagcacttcc tctccctgtc cgctcctcacc 60
 gtccctcctcg ggctgagcag caacctcacc gccggc 96

<210> 4
 <211> 188
 <212> PRT
 <213> Homo sapiens

```

<400> 4
Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu Val Leu Ser Cys
 1          5          10          15
Lys Ser Ser Cys Ser Val Gly Cys Asp Leu Pro Gln Thr His Ser Leu
 20          25          30
Gly Ser Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser
 35          40          45
Leu Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu
 50          55          60
Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His
 65          70          75          80
Glu Met Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser
 85          90          95
Ala Ala Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr
100          105          110
Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val
115          120          125

```

Thr Glu Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys
 130 135 140
 Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro
 145 150 155 160
 Cys Ala Trp Glu Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu
 165 170 175
 Ser Thr Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu
 180 185

<210> 5
 <211> 165
 <212> PRT
 <213> Homo sapiens

<400> 5
 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
 20 25 30
 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
 35 40 45
 Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
 50 55 60
 Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
 65 70 75 80
 Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
 85 90 95
 Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
 100 105 110
 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 115 120 125
 Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 130 135 140
 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 145 150 155 160
 Leu Arg Ser Lys Glu
 165

<210> 6
 <211> 31
 <212> PRT
 <213> Oryza sativa

<400> 6
 Met Gln Val Leu Asn Thr Met Val Asn Lys His Phe Leu Ser Leu Ser
 1 5 10 15
 Val Leu Ile Val Leu Leu Gly Leu Ser Ser Asn Leu Thr Ala Gly
 20 25 30

<210> 7
 <211> 31
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Modified rice alpha-amylase signal peptide

<400> 7
 Met Gln Val Leu Asn Thr Met Val Asn Lys His Phe Leu Ser Leu Ser
 1 5 10 15
 Val Leu Ile Val Leu Thr Val Leu Ser Ser Asn Leu Thr Ala Gly
 20 25 30

<210> 8
<211> 21
<212> PRT
<213> Arabidopsis thaliana

<400> 8
Met Lys Thr Asn Leu Phe Leu Phe Leu Ile Phe Ser Leu Leu Leu Ser
1 5 10 15
Leu Ser Ser Ala Glu
20

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 01/23400

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N15/67 C12N15/62 C07K14/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CAB Data, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 07210 A (RAJBHANDARI NIRMALA ; UNIV NORTH CAROLINA (US); STOMP ANNE MARIE (U) 18 February 1999 (1999-02-18)	1-5, 8-11, 14-24, 26-28 29,31
Y	page 4 -page 15; claims 1,12-14,21,29-31,38,46-59; example 48	
X	WO 99 19497 A (PERL AVIHAI ; EDELMAN MEIR (IL); FLAISHMAN MOSHE (IL); YEDA RES & D) 22 April 1999 (1999-04-22) page 4; claims 1-10; examples 12-15 page 9 -- -/-	1,2,8, 14-18, 23,26-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

8 October 2002

Date of mailing of the international search report

15/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MURRAY E E ET AL: "CODON USAGE IN PLANT GENES" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 17, no. 2, 25 January 1989 (1989-01-25), pages 477-498, XP000008653 ISSN: 0305-1048 the whole document ---	29, 31
Y	WO 99 47678 A (NORDSTROM JEFF ;RALSTON ROBERT (US); ROLLAND ALLAIN (US); GENEMEDI) 23 September 1999 (1999-09-23) the whole document ---	29
A		19-22
Y	EP 0 141 484 A (BIOGEN NV) 15 May 1985 (1985-05-15) the whole document ---	29
Y	WO 98 36085 A (APPLIED PHYTOLOGICS INC ;RODRIGUEZ RAYMOND L (US); SUTLIFF THOMAS) 20 August 1998 (1998-08-20) the whole document ---	31
A		3, 24, 25, 32-34
A	WO 94 21796 A (PIONEER HI BRED INT ;US AGRICULTURE (US)) 29 September 1994 (1994-09-29) the whole document -----	3, 7, 13, 34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 01/23400

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9907210	A	18-02-1999	AU 8779998 A	01-03-1999
			CN 1272762 T	08-11-2000
			EP 1037523 A1	27-09-2000
			JP 2001513325 T	04-09-2001
			WO 9907210 A1	18-02-1999
WO 9919497	A	22-04-1999	WO 9919497 A1	22-04-1999
			AU 4570397 A	03-05-1999
			AU 9457298 A	03-05-1999
			CA 2312008 A1	22-04-1999
			EP 1021552 A1	26-07-2000
			WO 9919498 A1	22-04-1999
WO 9947678	A	23-09-1999	AU 3000399 A	11-10-1999
			CA 2323604 A1	23-09-1999
			EP 1064383 A2	03-01-2001
			JP 2002506647 T	05-03-2002
			WO 9947678 A2	23-09-1999
EP 0141484	A	15-05-1985	EP 0141484 A2	15-05-1985
			JP 60070083 A	20-04-1985
WO 9836085	A	20-08-1998	AU 746826 B2	02-05-2002
			AU 6171698 A	08-09-1998
			EP 0981635 A1	01-03-2000
			JP 2001512318 T	21-08-2001
			WO 9836085 A1	20-08-1998
			US 6127145 A	03-10-2000
			US 6066781 A	23-05-2000
WO 9421796	A	29-09-1994	US 5569828 A	29-10-1996
			AU 6521494 A	11-10-1994
			WO 9421796 A2	29-09-1994

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)